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Dissertation Abstract
Cystic fibrosis is a genetic disorder that results from mutations in the CF
transmembrane conductance regulator gene. These mutations cause a disruption in
the chloride transport in mucosal tissues causing the accumulation of dehydrated
mucus, and a decrease in the mucocilliary removal of environmental pathogens within
the lungs. Additionally, the accumulation of dehydrated mucus within the lungs provides
a hospitable environment for various bacteria, including the Gram-negative opportunistic
pathogen Pseudomonas aeruginosa. P. aeruginosa uses the overproduction of a
surface polysaccharide called alginate to form a biofilm to evade the host’s
immunological defenses. The overproduction of alginate, often referred to as mucoidy,
is a virulence factor that is responsible for chronic P. aeruginosa infections, as well as
an increased resistance to antibiotics and phagocytosis by the host defense cells.
Chronic P. aeruginosa infections are the leading cause of morbidity and mortality in CF
patients, and the detection of mucoid isolates is a proven predictor of a decline in the
patient’s health. The transition from the non-mucoid phenotype, found in environmental
isolates, to the mucoid phenotype found within the CF lung is typically due to “loss-offunction” mutations in the transmembrane anti-sigma factor MucA.

However, P.

aeruginosa can overproduce alginate independent of mutations in mucA, through the
regulated proteolysis of MucA.

A series of proteases, beginning with AlgW, can

degrade MucA, and release the alternative sigma factor AlgU to drive transcription of
the alginate biosynthetic operon. It is generally accepted that the regulated proteolysis
of MucA is a mechanism used by early colonizing strains prior to the selection for MucA
mutations.

Therefore, understanding this mechanism employed by those early

colonizing strains may prove beneficial in preventing the establishment of chronic P.
x

aeruginosa respiratory infection.

In this dissertation, I identify and characterize two

novel regulators of alginate overproduction in P. aeruginosa strains possessing a wildtype MucA. Using the model strain PAO579, I determined that mutations that result in
the truncation of the type-IV pilin precursor protein, PilA, can induce alginate
overproduction through activation of the AlgW resulting in an increased rate of
proteolysis of MucA.

Additionally, I identify that expression of the genetic locus

PA1494, referred to as mucoid inhibitor A (muiA), can suppress mucoidy in P.
aeruginosa strains with a wild-type MucA. Collectively, these findings provide needed
insight into the regulation of mucoidy in those early colonizing strains, as well as
identifies potential therapeutic targets for the prevention of chronic P. aeruginosa
infections in the CF lung.

xi

CHAPTER 1: Introduction and Literature Review
Cystic Fibrosis
Cystic fibrosis (CF) is an autosomal recessive genetic disorder predominantly
associated with individuals of European descent.

CF afflicts approximately 30,000

individuals in the United States and 70,000 worldwide, with about 1,000 new cases
being diagnosed each year.

CF is the result of mutations in the cystic fibrosis

transmembrane conductance regulator gene (CFTR), located on the long arm of
chromosome 7 at locus q31.2.

Currently, >1,500 mutations in CFTR have been

identified that cause CF, with the most common being a deletion of a single codon for
phenylalanine at amino acid position 508 (ΔF508). The ΔF508 mutation is found in over
90% of all CF cases in the United States, and approximately 70% worldwide (8).
CFTR is categorized as an ATP-binding cassette membrane transporter, and is
responsible for the export of chloride ions (Cl-) across epithelial membranes. Disruption
in the CFTR gene causes a decrease in export of chloride ions to the surface of
epithelial cells.

Chloride ions are required to attract water molecules to sufficiently

hydrate the epithelial cell surface. Following the loss of chloride export and hydration of
the epithelial cells, a thick, dehydrated mucus accumulates. This accumulated mucus
affects several organ systems including the lungs, liver, pancreas and gastrointestinal
tract.

Symptoms associated with CF include salty-tasting sweat, poor growth and

weight gain, constipation, frequent chest infections, coughing, shortness of breath and
infertility.
Of particular importance, with regards to the overall morbidity and mortality of CF
patients, is the accumulation of mucus within the lungs. This accumulation causes a
1

decrease in mucociliary removal of microbial pathogens, and provides a hospitable
environment for their cultivation (6, 15, 73). Indeed, microbial infection is the leading
cause of mortality in individuals with CF (35).

However, the spectrum of microbial

pathogens that are associated with CF pulmonary infections is limited.

Those

pathogens that are associated with CF pulmonary infections are primarily bacterial and
include Burkholderia cepacia, Haemophilus influenza, Pseudomonas aeruginosa and
Staphylococcus aureus. Initial colonization by bacterial pathogens occurs early in life
(<1 year), with 50-60% caused by S. aureus. However, starting in adolescents, P.
aeruginosa surpasses S. aureus to become the leading cause of morbidity and mortality
among bacterial pathogens associated with CF (35).

Increased susceptibility of CF

patients to bacterial infections is likely due to a direct interaction of microbes with the
mutated CFTR protein (61, 62). However, Parker et al. suggest that mutations in CFTR
provide an opportunity for microbial cultivation because of a decrease in immune
surveillance due to disruptions in type-I interferon signaling (57). Additionally, mice
possessing CFTR mutations were unable to properly to kill phagocytosed bacteria due
to poor lysosomal acidification (25). Therefore, the function of CFTR mutation with
regards to the increased susceptibility in CF lungs is still not completely understood.
Historically, individuals with CF did not live past infancy.

However, due to the

implementation of second and third generation antibiotics, as well as improved
therapeutics, CF patients are able to live well into adulthood, with the average lifespan
being 37.5 years of age (Cystic Fibrosis Foundation).

Ultimately, increased mortality

rates in all CF patients is due to the “overwhelming sequelae of repeated pulmonary
exacerbations arising from persistent P. aeruginosa colonization” (35).
2

Pseudomonas aeruginosa and Biofilms
Pseudomonas aeruginosa is a motile, Gram-negative bacterium that is found
throughout the environment.

P. aeruginosa is also classified as an opportunistic

pathogen and has been linked to severe infections in immuno-compromised individuals,
such as burn victims (40), those afflicted with HIV/AIDS (2, 78), and pediatric patients

Figure 1. Mucoid phenotype in P. aeruginosa. Shown on the left side of the illustration is a mucoid P.
aeruginosa strain (PAO579), and on the right is the nonmucoid progenitor strain PAO1. The bacteria are
cultured on plates containing Pseudomonas isolation agar (PIA) and were incubated at 37⁰C for 24 hours and
then at room temperature for 24 hours.

undergoing chemotherapy (11, 81). P. aeruginosa has also been shown to successfully
colonize abiotic surfaces of equipment and vehicles used in space exploration (12).
Moreover, P. aeruginosa is the leading cause of hospital-acquired pneumonia and
bacteremia by a Gram-negative pathogen (26, 39).
P. aeruginosa is particularly adept at establishing chronic infections in individuals
with CF through the formation of a biofilm. The term “biofilm” was first introduced in
1977, and is used to define a collection of bacteria adhered to a surface surrounded by
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a self-produced exopolysaccharide matrix (37, 64).

Biofilm formation confers a

selective advantage upon the bacteria. Specifically with P. aeruginosa biofilms, there is
an increased resistance to antimicrobial therapies (17, 18, 47, 59, 79, 80), increased
protection against opsonization (49, 52, 63), and decreased engulfment by amoeba and
macrophages (10, 36, 45, 46, 54). Current estimates are that the vast majority of all
pathogenic P. aeruginosa infections, and 80% of all microbial infections, are due to
biofilm formation.
A biofilm is both functionally and morphologically different from a single free-floating,
or planktonic, bacterium.

Moreover, the formation of a bacterial biofilm is often

compared to the developmental processes associated with multi-cellular organisms. A
biofilm develops in four distinct stages:

attachment, development of microcolonies,

maturation, and dispersal (18, 74, 82). Initially, planktonic cells use flagella, type-IV pili
and other outer membrane adhesion proteins to adhere to biotic or abiotic surfaces (55).
Following initial adherence, the bacteria transition into microcolonies through the
production of an extracellular matrix consisting primarily of an extracellular polymeric
substance (EPS), or exopolysaccharide. In P. aeruginosa, the exopolysaccharides Psl
and Pel are involved in this initial stage of biofilm development (34, 41). The regulation
of Psl and Pel is often facilitated through cell-density dependent signaling or quorum
sensing. Two quorum-sensing systems, las and rhl, are used in P.aeruginosa (58).
During the maturation stage, the biofilm increases in population and volume and
begins to take on a three dimensional structure. In P. aeruginosa, this is due to an
overproduction of an exopolysaccharide called alginate (30, 35). The terminal stage of
biofilm development, dispersal, is marked by the evacuation of the bacteria following a
4

return to the planktonic state (18, 74). This transition the planktonic state is often in
response to environmental signals such as changes in pH, the concentrations of carbon
and oxygen, the presence of nitric oxide, the presence of heavy metals, as well as the
presence of various quorum-signaling molecules (4, 5, 38, 43, 75).

Interestingly, the

use of alginate in this maturation stage of biofilm development is generally not found
outside of the CF lung, and is indicative of a chronic infection (35). Moreover, alginate
is not used by nonmucoid, environmental isolates of P. aeruginosa in the formation of
biofilms (89).
Alginate Production and Regulation
In the CF lung, the transition of P. aeruginosa between initial attachment and the
development

of

mature

biofilm

is

marked

by

the

overproduction

of

the

exopolysaccharide alginate. Alginate is a biopolymer consisting of two monomers of βD-mannuronate acid and its epimer α-L-guluronate. Overproduction of alginate is often
referred to as the mucoid phenotype, or simply mucoidy. The emergence of mucoid
isolates from CF patient sputa is indicative of a chronic infection, and is pathognomic for
both CF and P. aeruginosa (24, 35) . Additionally, the conversion from the nonmucoid
to the mucoid phenotype is considered a prognostic marker for the poor overall health of
the CF patient (35).

5

Table 1. Summary of the alginate biosynthetic operon
Gene

Gene

MW

Predicted

References

Locus

Name

(kDa)

Localization

Product Name

PA3540

algD

47.6

Cytoplasm

GDP-mannose 6-dehydrogenase

(22, 23)

PA3541

alg8

56.5

Inner Membrane

glycosyltransferase

(48, 56, 70)

PA3542

alg44

41.8

Inner Membrane

c-di-GMP binding-activation/membrane fusion protein

(48, 53, 71)

PA3543

algK

52.5

Periplasm

periplasmic multi-protein complex

(44)

PA3544

algE

54.4

Outer Membrane

outer membrane protein (porin)

(16, 68, 85)

PA3545

algG

59.8

Periplasm

alginate C5-epimerase

(14, 28)

PA3546

algX

52.6

Periplasm

alginate o-acetyltransferase

(72, 84)

PA3547

algL

40.8

Periplasm

poly(β-D-mannuronate) lyase

(1, 42)

PA3548

algI

58.7

Inner Membrane

alginate o-acetyltransferase

(29, 32, 33)

PA3549

algJ

43.1

Inner Membrane

alginate o-acetyltransferase

(29, 32, 33)

PA3550

algF

22.8

Periplasm

alginate o-acetyltransferase

(29, 31, 33)

PA3551

algA

53.1

Cytoplasm

phosphomanose isomerase/guanosine 5’-D-mannose

(21, 60)

pyrophosphorylase
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The overproduction of alginate in P. aeruginosa is the result of increased expression
of the alginate biosynthetic operon (22). The alginate biosynthetic operon is located
between genome positions 3,962,825 and 3,979,476 in the reference strain PAO1, and
consists of 12 genes responsible for the manufacture, assembly and export of the
alginate polymer across the periplasmic space to the extracellular matrix (Table 1). The
regulation of the entire alginate biosynthetic operon occurs at a single promoter site
upstream of the algD gene (P algD ). Transcription at P algD is primarily controlled by the
alternative
factor

AlgU

sigma
(also

known as AlgT, σ22,
σE)

(50,

88).

Increased expression
of

AlgU

also

modulates the two-

Figure 2. Regulation of the algU-mucA-mucB-mucC-mucD operon. The
regulation of the algUmucABCD operon occurs at five promoter sites (P1-P5)
upstream of algU. Expression of algU and its subsequent negative regulators,
mucA, mucB and mucD, is auto-regulated at the P1 and P3 promoter sites. (+)
and (-) identify the associated gene as a positive or negative regulators of algU,
respectively. (?) signifies either unknown function or transcriptional regulator.

component regulators, AlgB and AlgR, as well as the transcription factor AmrZ (67).
Subsequently, the increased expression of AlgB, AlgR, and AmrZ, which directly bind to
different sites upstream of algD, also causes an increase in activity at P algD and mucoidy
(7, 67, 76, 88). Therefore, the initiation of the alginate biosynthetic operons hinges
upon the regulation of AlgU.
The algU gene (PA0762) is found at the 5’ end of an operon containing the negative
regulators mucA (PA0763), mucB (PA0764) and mucD (PA0766) (Figure 2). AlgU is
localized in the cytoplasm and is a stress-related alternative sigma factor, which
belongs to a superfamily of sigma factors known to control extra-cytoplasmic function
7

(ECF). MucA is the cognate anti-sigma factor for AlgU, and is associated at its Cterminus with the periplasmic protein MucB (51).

MucB is thought to improve the

stability of MucA by protecting its periplasmic portion from proteolytic degradation. The
mucC gene codes for a 15.9 kDa protein of unknown function. The algU-mucA-mucBmucC-mucD operon is regulated transcriptionally by 5 promoters (P1-P5) upstream of
algU. P1 and P5 are constitutively active in nonmucoid P. aeruginosa strains with a
wild-type MucA, while P1 and P3 are AlgU-dependent and responsive to external
stressors (77). MucD is a homolog of DegP in E. coli, and is classified as a periplasmic
chaperone-protease.

Inactivation of MucD causes mucoidy in P. aeruginosa strain

PAO1 (20, 66).
The positive regulation of alginate overproduction is primarily attributed to AlgU and
its cognate anti-sigma factor MucA. MucA is a transmembrane protein that spans the
inner membrane, with the C-terminus and N-terminus localized in the periplasm and
cytoplasm, respectively.

In a nonmucoid wild-type P. aeruginosa strain, AlgU is

sequestered by MucA to the cytoplasmic leaflet of the inner membrane. This prevents
AlgU from moving freely about the cytoplasm and initiating transcription of the alginate
biosynthetic operon at the algD promoter site, as well as the promoter sites for the
additional modulators of alginate biosynthesis, algB, algR and amrZ.

8

Currently there are two mechanisms identified by which AlgU is released from MucA.
The first is through the abrogation of MucA. In the majority of clinical CF isolates,
selective pressure causes the emergence of mucoid isolates through the selection of
MucA mutants (3, 9). This is commonly due to frameshift or insertion/deletion (INDEL)
mutations that result in a
complete loss of function
or diminished function due
to

the

translation

of

truncated MucA protein.
The truncated protein has
decreased overall stability
when compared to the
wild-type, full length MucA
Figure 3. Mutations in MucA cause mucoidy in Pseudomonas
aeruginosa. In the nonmucoid PAO1 strain, the alternative sigma factor
AlgU is sequestered to the inner membrane. The emergence of mucoid
isolates in the CF lung is typically due to mutations in that either abrogate
or truncate the gene for the transmembrane anti-sigma factor MucA. The
loss of function for MucA causes the release of AlgU and an increase in
expression of the alginate biosynthetic operon at the algD promoter site.
AlgU also modulates expression of the algB, algR and amrZ. Previously it
has been shown that the proteases Prc and ClpXP are required for
mucoidy in the truncated MucA strains mucA22 and mucA25, respectively.

(65). Interestingly, Reiling
et al. reported that the
periplasmic protease Prc
is required for mucoidy in
the

truncated

MucA

mutant, mucA22, but not in strains possessing a wild-type MucA (69). Prc has both a
PDZ and a tail-specific protease domain; however the substrate specificity is not fully
understood.

Additionally, the cytoplasmic protease complex ClpXP is required for

mucoidy in the truncated MucA mutant, mucA25 (65).
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Hypothetically, the site-2

protease MucP (YaeL) could degrade the intramembrane portion of the truncated MucA;
however no data confirming this hypothesis is currently available (19).
The second mechanism for the release of AlgU involves the regulated
intramembrane proteolysis (RIP) of wild-type MucA.

More specifically, MucA is

systematically degraded by a series of proteases beginning in the periplasm with AlgW,
continuing with the site2

intramembrane

protease

MucP,

and

with

the

completed
cytoplasmic

protease

complex ClpXP (Figure
4).

AlgW, a serine

protease
functional

and

a

homologue

of DegS in E. coli,
contains an N-terminal
anchor, a PDZ domain
and a protease domain
(27, 66, 86). Activation

Figure 4. Activation of mucoidy through regulated intramembrane
proteolysis (RIP). When activated by the presence of stress agents (not
shown) or the accumulation of envelop proteins, the serine protease AlgW
can positively regulate AlgU by cleaving the periplasmic portion of MuA.
This is followed by proteolytic cleavage of the intramembrane portion of MucA
by the site-2 metalloprotease MucP. The protease complex ClpXP degrades
the cytoplasmic portion of MucA. AlgU is now free to drive transcription of the
alginate biosynthetic operon at the algD promoter, as well as the algB, algR
and amrZ.

of AlgW results in the cleavage of MucA at a major cut site between the alanine residue
at position 136 and the glycine residue at position 137 (13). Activation of AlgW occurs
in response to the presence of external stress agents, such as D-cycloserine (86).
Additionally, the overexpression of the small periplasmic protein MucE (PA4033)
10

induces mucoidy via AlgW in the nonmucoid strain PAO1 (66). This activation of AlgW
is due to an interaction between the C-terminal motif of tryptophan-valine-phenylalanine
(WVF) of MucE and the PDZ domain of AlgW (13, 66, 83). MucP is also required for
activation of mucoidy in both the presence of D-cycloserine and the overexpression of
MucE (66, 87).

MucP possesses two PDZ domains and a zinc metallo-proteolyic

domain consisting of a motif of histidine-glutamic acid-X-X-histidine (HExxH), which is
required for alginate overproduction (20).

It has also been proposed that the

cytoplasmic portion of MucA is degraded by the ClpXP complex following cleavage by
MucP (65). Following the complete degradation of the wild-type MucA, AlgU is free to
drive transcription of the alginate biosynthetic operon at the PalgD promoter site, as well
as modulate transcription of algB, algR and amrZ.

11

Dissertation Introduction
Colonization of the CF lung by P. aeruginosa via infiltration of nonmucoid
environmental strains with a wild-type MucA, and natural selection for mutations in
MucA that provide protection from the host’s defenses through biofilm formation using
the overproduction of alginate is the current dogma for the evolution of chronic
P.aeruginosa infections in CF patients. Although, the majority of mucoid CF isolates
possess mutations in MucA, regulated proteolysis of MucA is proposed as the
mechanism for biofilm formation used by those early colonizing strains. Therefore, the
goal of my study was to identify novel regulators of alginate overproduction in P.
aeruginosa strains with a wild-type mucA. To achieve this goal, I used a prototypic
mucoid strain PAO579 as the model system (shown in Figure 1). PAO579 possesses a
wild-type mucA and is mucoid via an unclassified mutation referred to as muc23.
Additional details regarding the origin of PAO579 are described in Chapters 2 and 3. I
used whole genome sequencing to identify the muc23 mutation. The parameters and
results are provided in Chapter 2. In Chapter 3, I describe the use these sequencing
results, as well as various molecular and microbiological techniques, to determine that
mucoidy in PAO579 is due to three tandem mutations in the gene locus PA4525. These
three tandem mutations result in a truncation in the type-IV pilin precursor protein, PilA,
which activates the regulated proteolysis of MucA via AlgW. In Chapter 4, I describe
the use of complementation and in vitro transposon mutagenesis of a whole genome
cosmid library, derived from the reference strain PAO1, to identify novel inhibitors of
alginate production in PAO579. I identified gene locus PA1494 that can inhibit alginate
overproduction after localization of the gene product to the periplasm. As set forth in
12

Chapter 5, I explore the relationship between the expression of gene locus PA1494 and
the periplasmic chaperone/protease MucD. These chapters identify and detail both the
positive and negative regulatory pathways involved in mucoidy in the P. aeruginosa
strain PAO579. The summation of these chapters, as well as the proposal of new
questions and ideas, is found in Chapter 6. Collectively, the research described in this
dissertation identifies novel mechanisms for the genetic regulation of alginate
production in Pseudomonas aeruginosa. More importantly, it provides insights that may
aid in the suppression of biofilm formation in the CF lung.
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Chapter 2 Overview and Rationale
In this study, I used the model strain PAO579 to identify novel regulators of
mucoidy in P. aeruginosa strains possessing a wild-type MucA. PAO579 is a mucoid
mutant derived from the non-mucoid progenitor strain PAO1. The genetic mutation(s)
responsible for mucoidy in PAO579 is unknown and is referred to as muc-23. In order
to identify potential candidates for the muc-23 mutation, I used next-generation
sequencing technology to sequence the entire genome of PAO579, and compared it to
the previously published PAO1 reference genome. These results are presented and
discussed in this chapter.
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Abstract
Pseudomonas aeruginosa is an opportunistic pathogen that establishes a chronic
infection in individuals afflicted with cystic fibrosis. Here we announce the draft genome
of P. aeruginosa strain PAO579, a mucoid derivative of strain PAO381.
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Pseudomonas aeruginosa is a ubiquitous, opportunistic pathogen and the
leading cause of mortality in individuals afflicted with cystic fibrosis. P. aeruginosa uses
the overproduction of an exopolysaccharide, called alginate, to form biofilms. Biofilm
formation is responsible

PAO1: Prototroph AlgStanisich & Holloway; 1969

for the development of
chronic infections, as well

-

PAO381: PAO1 Alg leu38 strA2 mucA

+
as increased resistance to

Govan & Fyfe; 1980

+

+

antibiotic

treatment

(2),

PAO579: PAO381 Alg leu38 strA2 mucA muc23

and reduced phagocytosis

Figure 1. Origin of P. aeruginosa strain PAO579. PAO579 was derived
from a series of mutagenic experiments beginning with bacteriophagemediate mutagenesis of PAO1 yielding PAO381. Next, mucoid mutants
were isolated following exposure of PAO381 to sub-lethal concentrations of
+
carbenicillin. Alg =nonmucoid; Alg =mucoid; leu38=leucine auxotrophic;
+
strA2=streptomycin resistant; mucA =wild-type mucA; muc23=unclassified
mutation(s).

by macrophages (4).

P.

aeruginosa strain PAO579
was

first

mucoid

isolated
variant

as
of

PAO381, a derivative of the non-mucoid strain PAO1 (3, 5). Both PAO579 and PAO381
have a wild-type mucA (mucA+), and both strains are leucine auxotrophic (leu38) and
streptomycin resistant strains (strA2).
Genomic DNA from P. aeruginosa strain PAO579 was isolated using
phenol/chloroform extraction and ethanol precipitation, and paired-end sequencing
libraries were generated using vendor protocols (Illumina, San Diego, CA) and genome
sequencing was performed on an Illumina GAIIX with a total of 54, 496, 482 60-bp
paired-end reads resulting in 3, 269, 788, 920 bp for ~500x coverage.

Data was

generated and assembled using Illumina Pipeline version SCS 2.8.0 paired with OLB
1.8.0, and aligned and annotated according the P. aeruginosa strain PAO1 reference
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genome (GenBank accession no. NC_2516.2) using NovoAlign version 2.07.10. All
specifics regarding aligner algorithms can be obtained from novocraft.com. Further
analysis of the genome was performed using Samtools version 01.16a for the
generation of pileup after sorting and removing duplicate reads, and then applying
analysis pipeline software developed by CoFactor Genomics (St. Louis, MO, USA). The
genome was annotated and prepared for submission using NCBI Prokaryotic Genomes
Automatic

Annotation

Pipeline

(PGAAP; http://www.ncbi.nlm.nih.gov.genomes/static/Pipeline.html) server at NCBI.
Based upon our analysis, single nucleotide polymorphisms (SNPs) and INDELS
were observed between the sequenced reads and the PAO1 reference genome and
were tabulated for each genomic position, as well as the total coverage of bases
observed at that location. As a result, 16 non-synonymous and 15 synonymous single
nucleotide polymorphisms (SNPs) were identified using two criteria:

more than 4X

coverage and greater than 60% frequency. This data is shown in Table 1. Of particular
interest is the substitution of thymine for adenine at genome position 4980548 in the
DegS-like MucA protease gene, algW (PA4446). This alteration results in a change in
the primary structure of AlgW, more specifically a substitution of isoleucine for
phenylalanine at amino acid position 239. This predicted substitution is thought to effect
the proteolytic activity of AlgW (1).

Also of note, we observed mutations in leuA

(PA3792), 2-isopropylmalate synthase, and rpsL (PA4268), 30S ribosomal protein S12.
These mutations are contiguously part of the PAO381 lineage, and are responsible for
leucine auxotrophy and streptomycin resistance, respectively.
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Nucleotide sequence accession number.

The draft genome sequence of P.

aeruginosa strain PAO579 has been deposited in GenBank under accession number
AFLOF00000000.
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Table 1. Complete sequencing results for PAO579
SNP

Genome
Position

Change

SNP Position
(Gene Size)

ORF

Gene
Name

Gene Product

Protein

1

5036891

A→C

-183(1602)

PA4500
rpsL

Probable binding protein
component of ABC transporter
30S ribosomal protein S12

2

4771865

T→C

263(372)

PA4268

K88R+

3

183697

T→G

930(939)

PA0159
PA3792

leuA

Probable LysR transcriptional
regulator
2-isopropylmalate synthase

4

4251149

G→A

322(1779)

E108K+

5

6115455

T→G

858(1254)

PA5434

mtr

Tryptophan permease

K266N

6

4980548

A→T

715(1170)

PA4446

algW

DegS-like serine protease

I239F

7

4924552

C→G

532(837)

PA4394

yggB

Conserved hypothetical protein

V178L+

8

4924553

G→C

531(837)

PA4394

yggB

Conserved hypothetical protein

9

6098781

G→C

1758(3018)

PA5418

soxA

Sarcosine oxidase α subunit

10

1871272

T→C

157(342)

PA1728

11

4212201

A→G

1907(2529)

PA3760

nagF

12

1589438

G→C

101(1107)

PA1459

13

6079222

A→G

1179(1962)

PA5399

27

C310W

Hypothetical protein

S53P
H636R

cheB

N-acetyl-D-Glucosamine
phosphotransferase system
transporter
Probable methyl-transferase

dgcB

Dimethylglycine catabolism

G34A

14

5743462

G→C

1292(1680)

PA5100

hutU

Urocanase

15

5743461

C→G

1293(1680)

PA5100

hutU

Urocanase

16

4869855

T→G

474(771)

PA4341

17

4344266

A→G

570(1296)

PA3877

nark1

Probable IcIR transcriptional
regulator
Nitrite extrusion protein 1

18

721611

C→T

(1200)+55

PA0668

tyrZ

tyrosyl-tRNA synthetase 2

19

2239547

T→G

-280(408)

PA2046

Hypothetical protein

20

413850

T→C

-196(291)

PA0369

Hypothetical protein

21

4334140

G→C

207(990)

PA3870

moaA1

22

4448855

C→G

(1500)+38

PA3970

amn

Molybdopterin biosynthetic
protein A1
AMP nucleosidase

23

4448856

G→C

(1500)+37

PA3970

amn

AMP nucleosidase

24

1603577

T→G

-94(759)

PA1477

ccmC

Heme exporter protein CcmC

25

5069207

G→A

325(450)

PA4525

pilA

Type IV fimbrial precursor

26

5069206

T→C

326(450)

PA4525

pilA

Type IV fimbrial precursor

Stop

27

5069205

C→T

327(450)

PA4525

pilA

Type IV fimbrial precursor

Stop

28

1440625

A→G

1920(1971)

PA1327

Probable protease

29

169284

G→C

-77(546)

PA0149

Probable σ70 factor, ECF

28

T431S+

E158D+

Stop

30

2768847

C→G

9958(16884)

PA2462

31

2813321

A→G

128(1419)

PA2495

oprN

Hypothetical protein

A3320P

Multidrug efflux outer

D43G

membrane protein
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Chapter 3 Overview and Rationale
In chapter 2, I identified 31 mutations unique to P. aeruginosa strain PAO579, as
compared to the previously published PAO1 reference genome. In order to determine
the specific mutation(s) responsible for mucoidy in PAO579, I used functional analyses
and PCR sequencing to narrow the search to two potential candidate loci.

Using

standard cloning and molecular techniques, I determined that three tandem mutations in
the pilA gene (pilA108) are responsible for the induction of mucoidy by activating the
serine protease AlgW to degrade MucA, thereby releasing the AlgU to drive transcription
of the alginate biosynthetic operon. Therefore, the three tandem mutations in the pilA
gene are the muc-23 mutation. These results are presented and discussed in this
chapter.
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Abstract
Pseudomonas aeruginosa is a Gram-negative, opportunistic pathogen that uses
the

overproduction

of

alginate,

a

surface

polysaccharide,

to

form

biofilms.

Overproduction of alginate, also known as mucoidy, affords the bacterium protection
from the host’s defenses and facilitates the establishment of chronic lung infections in
individuals with cystic fibrosis.

Expression of the alginate biosynthetic operon is

primarily controlled by the alternative sigma factor AlgU (AlgT/σ22). In a non-mucoid
strain, AlgU is sequestered by MucA, a transmembrane anti-sigma factor, to the
cytoplasmic membrane. AlgU can be released from MucA by regulated intramembrane
proteolysis by proteases AlgW and MucP, causing the conversion to mucoidy.

P.

aeruginosa strain PAO579, a derivative of the non-mucoid strain PAO1, is mucoid due
to an unidentified mutation (muc-23). Using whole genome sequencing, we identified
16 non-synonymous and 15 synonymous single nucleotide polymorphisms. We then
identified three tandem single point mutations in the pilA gene (PA4525), as the cause
of mucoidy in PAO579. These tandem mutations generate a premature stop codon
resulting in a truncated version of PilA (PilA108), with a C-terminal motif of phenylalaninethreonine-phenylalanine (FTF).
mucoidy.

Deletion of pilA108 confirmed it was required for

Additionally, algW and algU were also required for mucoidy of PAO579.

Western blot analysis indicated that MucA was less stable in PAO579 than non-mucoid
PAO1 or PAO381. The mucoid phenotype and high P algU and P algD promoter activities
of PAO579 require pilA108, algW, algU and rpoN. We also observed that the alternative
sigma factor RpoN regulates expression of algW and pilA in PAO579. Together, these
results suggest that truncation in PilA can induce mucoidy through an AlgW/AlgU-
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dependent pathway.
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Introduction
Cystic fibrosis (CF) is a genetic disorder that results from mutations in the CF
transmembrane conductance regulator gene (32). These mutations cause a disruption
in chloride transport of mucosal tissues resulting in an accumulation of dehydrated
mucus. This accumulation of mucus within the lungs prevents the removal of infectious
agents by interfering with the mucociliary escalator (6). This provides a hospitable
environment for the adherence and cultivation of microbial pathogens (2, 34). As a
result, individuals afflicted with CF are highly susceptible to various bacterial infections
including P. aeruginosa (13).

This bacterium is a Gram-negative, opportunistic

pathogen that uses the overproduction of alginate, a surface polysaccharide, to form
biofilms. The overproduction of alginate, also known as mucoidy, is responsible for the
establishment of chronic infections, as well as an increased resistance to antibiotics (13)
and phagocytosis by macrophages (21) in CF patients. Chronic lung infections with P.
aeruginosa cause an increase in morbidity and mortality in individuals afflicted with CF
(22), and this transition from the non-mucoid to the mucoid phenotype is a proven
predictor of an overall decline in the patient’s health (16).

Typically, constitutively mucoid strains arise in the lungs of CF patients due to
mutations in the mucA gene which encodes the inner membrane-spanning anti-sigma
factor (4, 23).

MucA is a negative regulator of alginate overproduction due to

sequestering AlgU (AlgT, σE, σ22), the primary sigma factor responsible for activation of
the alginate biosynthetic operon at the algD promoter (40). Alternatively, the conversion
to mucoidy can occur when MucA is degraded by regulated intramembrane proteolysis
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which will release AlgU (31). Proteolytic degradation is initiated through cleavage of the
C-terminus of MucA between the alanine and glycine at position 136 by the serine
protease AlgW (5), anchored in the periplasmic leaflet of the inner membrane, and
followed by the transmembrane protease MucP (YaeL) and the cytoplasmic proteases
ClpX and ClpP (5, 7, 30, 31). The activation of AlgW, and subsequent proteolysis of
MucA, is thought to be in response to extracellular stress, as well as the accumulation
of misfolded envelope proteins (31, 39). We previously found that induction of a small
envelope protein called MucE causes mucoidy (31). MucE has an AlgW activation
signal with a C-terminal motif of tryptophan-valine-phenyalanine (WVF) (31). The MucE
peptide is also a potent ligand that activates AlgW resulting in the degradation of the
periplasmic fragment of MucA (5).

P. aeruginosa strain PAO579 was first generated in the 1970s through the
isolation of mucoid variants of PAO381 (14), a non-mucoid derivative of the progenitor
strain PAO1, following exposure to a sub-lethal concentration of carbenicillin. PAO579
is highly mucoid due to unclassified mutation(s) that is referred to as muc-23 (14).
Mucoidy in PAO579 depends on the alternative sigma factor RpoN (σ54) (3). In this
study, we used whole genome sequencing to identify mutation(s) that cause the
mucoidy of PAO579. We found three tandem mutations in pilA that are responsible for
the mucoid phenotype in this strain.

Moreover, the mucoid phenotype of strain

PAO579 is dependent upon AlgW, as well as AlgU and RpoN. Our data suggests
truncation of pilin induces mucoidy in P. aeruginosa strain PAO579.
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Experimental Procedures
Sequence analysis of PAO579. Methods and parameters used in the sequencing of
P. aeruginosa strain PAO579 were previously described (37).

Bacterial strains and growth conditions. Bacterial strains used in this study are
indicated in Table 1. P. aeruginosa and E. coli strains were grown at 37°C in Lennox
broth (LB), on LB agar, or Pseudomonas Isolation Agar (PIA). When indicated, the
media was supplemented with carbenicillin, gentamycin, tetracycline, kanamycin and/or
arabinose.

Construction of mutant strains. In-frame deletion of target genes algU (PA0762) and
algW (PA4446) in PAO579 was performed through PCR amplification of the upstream
and downstream regions (500 to 1000 base pairs) flanking the target gene. Using
crossover PCR, these upstream and downstream regions were fused and ligated into
pEX100T-NotI. A two-step allelic exchange procedure was used by first screening the
possible deletions mutants for carbenecillin resistance and sucrose sensitivity, then
screening for sucrose resistance and carbenecillin sensitivity. For construction of the
PAO579rpoN::TcR strain, rpoN (PA4462) was amplified through PCR, cloned into the
pCR®4-TOPO® Vector (Invitrogen) and transformed into E. coli DH5α.

In vitro

transposon mutagenesis was performed on the pCR®4-TOPO®-rpoN vector using the
EZ::TN <KAN-2> insertion kit (Epicentre Biotechnologies).

The mutant library was

recovered and triparentally conjugated en masse into PAO579. Mutants were selected
on PIA containing tetracycline and screened for the non-mucoid phenotype.
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Table 1. Bacterial strains and plasmids used in this study.
Strain, Plasmid

Genotype, phenotype, description

Reference

E. coli
DH5α derivative

Invitrogen

PAO1

algU+mucA+; non-mucoid

P. Phibbs*

PAO381

algU+mucA+; non-mucoid, derived from PAO1

J. Govan**

PAO579

algU+mucA+muc-23; mucoid, derived from PAO381

J. Govan**

PAO579ΔalgU

mucA+muc-23, In-frame deletion of algU (PA0762); non-mucoid

This study

PAO579ΔalgW

algU+mucA+muc-23, In-frame deletion of algW (PA4446); non-mucoid

This study

PAO579pilA::aacC1

algU+mucA+muc-23, pilA::GmR (PA4525) encoding a Type-IVa pilin precursor; non-mucoid

This study

PAO579rpoN::TcR

algU+mucA+muc-23, rpoN:: TcR (PA4462) of the sigma factor RpoN (σ54); non-mucoid

This study

pCR4-TOPO

3.9-kb, ApR, KmR; TA cloning vector

Invitrogen

pRK2013

KmR, Tra Mob ColE1

(12)

pHERD20T

pUCP20T P lac replaced by 1.3-kb AflII-EcoRI fragment of araC-P BAD cassette

(29)

pHERD20T-algW

algW (PA4446) from PAO1 in pHERD20T; EcoRI/HindIII

This study

pHERD20T-algW I239F

algW (PA4446) from PAO579 in pHERD20T; EcoRI/HindIII

This study

pHERD20T-pilA

pilA (PA4525) from PAO1 in pHERD20T; EcoRI/HindIII

This study

pHERD20T-pilA108

pilA (PA4525) from PAO579 in pHERD20T; EcoRI/HindIII

This study

pHERD20T-pilA-HA

C-terminally tagged pilA-HA ending with the PKGCDN motif cloned in pHERD20T; EcoR1/HindIII

This study

TOP10
P. aeruginosa

Plasmids
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pHERD20T-pilA108-HA

C-terminally tagged pilA-HA ending with the DITFTF motif cloned in pHERD20T; EcoR1/HindIII

This study

pHERD20T-oprF

oprF (PA1777) from PAO1 in pHERD20T; EcoRI/HindIII

This study

pHERD20T-oprF-FTF

oprF (PA1777) from PAO1 with FTF-motif fused to the C-terminal; EcoRI/HindIII

This study

pHERD20T-HA-mucA

N-terminally tagged HA-mucA in pHERD20T; EcoRI/HindIII

(9)

pUCP20T-P BAD -rpoN

araC-P BAD -rpoN fusion in pUCP20; XbaI/HindIII

(9)

miniCTX-lacZ

Gene delivery system used to fuse target genes to lacZ and integrate onto the chromosome at the
CTX phage att site in P. aeruginosa, TcR

(17)

miniCTX-P algD -lacZ

Complete PalgD promoter (1,525 bp upstream of ATG) HindIII/BamHI in miniCTX-lacZ

(9)

miniCTX-P algU -lacZ

Complete P algU promoter (541 bp upstream of ATG) EcoRI/HindIII in miniCTX-lacZ

(9)

pEX100T-NotI

Pseudomonas suicide vector with NotI restriction site fuse into SmaI of pEX100T, sacB, oriT, CbR

(9)
(31)

pLP170

1.4-kb fragment flanking the algW (PA4446) gene ligated into pEX100T-NotI with in-frame deletion
of algW
2.5-kb fragment flanking the algU (PA0762) gene ligated into pEX100T-NotI with in-frame deletion
of algU with 24 bp remaining.
1941 bp fragment contained 966 bp upstream of ATG and 975 bp downstream of TAA with a MluI
GmR cassette (750 bp) inserted 9 bp before ATG of an in-frame deleted pilA ligated into pCR4TOPO
8.3-kb, lacZ, ApR, multiple cloning site

pLP170-P algU

Complete P algU promoter (541 bp upstream of ATG) fused with lacZ in pLP170 BamHI/HindIII

This study

pLP170-P algD

Complete P algD promoter (989 bp upstream of ATG) fused with lacZ in pLP170 BamHI/HindIII

This study

pLP170-P pilA

Complete P pilA promoter (500 bp upstream of ATG) fused with lacZ in pLP170 BamHI/HindIII

This study

pLP170-P algW

Complete P algW promoter (1,000 bp upstream of ATG) fused with lacZ in pLP170 BamHI/HindIII

This study

pEX100T-ΔalgW
pEX100T-ΔalgU
pCR4-pilA::GmR

*P. Phibbs, East Carolina University, Greenville, NC, USA.
**J. Govan, University of Edinburgh, Scotland, UK.
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(9)
This study

(28)

The PAO579pilA::aacC1 strain was constructed using crossover PCR of 1000 bp
upstream and downstream fragments of pilA (PA4525) containing an internal MluI
restriction site. This crossover PCR product was cloned into the pCR®4-TOPO® vector
and digested using MluI. A cassette containing a gentamycin resistance marker was
digested with MluI and ligated into the pCR®4-TOPO®-pilA construct.

Finally, the

pCR®4-TOPO®-pilA construct was triparentally conjugated and a two-step allelic
exchange procedure was used by first screening for gentamycin resistance and
carbenicillin resistance, then gentamycin resistance and carbenicillin sensitivity.

All

strains were amplified by PCR and sequenced to confirm proper insertion or deletion of
the target genes.
Plasmid construction and complementation. The plasmids used in this study are
indicated in Table 1. Standard recombinant DNA cloning techniques were used in the
construction of all plasmids used in this study (33). Briefly, oligonucleotide primers were
designed based on PAO1 sequence information and synthesized by Eurofin MWG
Operon. Primer sequence information is available in Table 1. PCR amplifications were
done using EasyStart™ Micro 50 PCR Mix-in-a-Tube (Molecular BioProducts) and Taq
DNA Polymerase (New England BioLabs). The pCR®4-TOPO® Vector (Invitrogen, Inc.)
was used as an intermediary before ligation into the target vector. All plasmids were
purified using QIAprep® Spin Miniprep Kit (Qiagen Sciences). All plasmid constructs
were sequenced to confirm they contained no mutations. Plasmids were transformed
into E. coli DH5α for all intermediate cloning steps.

Completed plasmids were

triparentally conjugated into target P. aeuginosa strains using pRK2013 as a helper
strain(12).
41

Alginate assay.

Alginate was measured using the previously published carbazole

reaction (19). Bacterial strains were streaked onto triplicate PIA plates, and incubated
at 37° C for 24 hrs. The bacterial cells were scraped into 10 mL of PBS and the OD 600
was recorded. The amount of uronic acid was measured and compared to an alginate
standard curve made with D-mannuronic acid lactone (Sigma-Aldrich) in the range 0 to
100 μg/mL.

The reported values represent an average of three independent

experiments with standard deviation.

β-galactosidase activity assay. Pseudomonas strains carrying the plasmid pLP170
(empty vector) or pLP170 containing P algD , P algU , P algW or P pilA or PAO1 miniCTX-P algU lacZ and miniCTX-P algD -lacZ with pHERD20T, pHERD20T-pilA or pHERD20T-pilA108
were cultured at 37°C on three PIA plates supplemented with carbenecillin or
carbenicillin and tetracycline. Bacterial cells were harvested, resuspended in PBS and
the OD 600 was recorded.

The cells were permeabilized using toluene, and β-

galactosidase activity was measured with results calculated and reported in Miller Units
(25). One Miller Unit equivalent to 1000 X (A 420 /-1.75 X A 550 /OD 600 mL-1 min-1). The
reported values represent an average of three independent experiments with standard
deviation. Student’s t test was performed to determine statistical significance.

Protein analyses.

Bacterial strains were grown at 37°C on PIA or LB media

supplemented with the appropriate antibiotics.
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Cells were harvest and whole cell

lysates were prepared using the ProteaPrep Cell Lysis Kit (Protea Biosciences) and the
total protein content was quantified using D c Assay (Bio-Rad).

Using a HA Tag

immunoprecipitation kit (Pierce®), HA-tagged proteins were isolated by combining cell
lysates with anti-HA agarose beads, incubating overnight at 4°C, washing with a TBSTween solution, and eluting the proteins from the anti-HA agarose beads.

The protein

samples (25 µg) were boiled for 10 min in Tricine Sample Buffer (Bio-Rad) and
electrophoresed on a 16.5% Tris-Tricine gel (Bio-Rad). Samples were then electroblotted onto a Hybond™-P PVDF transfer membrane (GE Healthcare). The membrane
was blocked using 3% skim milk/PBS.

Mouse monoclonal antibody for the alpha

subunit of RNA polymerase (Neoclone) and rat monoclonal antibody for hemagglutinin
(Roche Diagnostics) were used as primary antibodies. Anti-pilin serum was gifted from
the Lory laboratory (University of California, San Francisco, CA).

Horseradish

peroxidase-labelled goat anti-mouse IgG, goat anti-rabbit or goat anti-rat IgG were used
as secondary antibodies. Primary and secondary antibodies were diluted in 3% skim
milk/PBS to 1:5000 and 1:10,000, respectively. Western blot results were imaged using
ECL Advance Western Blotting Detection Kit (Amersham; GE Healthcare) and UVP
BioImaging Systems. When necessary, blots were stripped using 62.5 mM Tris-HCl pH
6.8, 2% SDS, 100 mM β-mercaptoethanol for 10 minutes at 40°C.

Epifluorescent microscopy.

Pseudomonas strains containing pHERD20T-pilA-HA-

PKGCDN (WT), pHERD20T-pilA-HA-DITFTF or pHERD20T were cultured on PIA plates
supplemented with 300 µg/mL carbenicillin and arabinose and incubated at 37°C. For
the detection of extracellular PilA, cells were stained according to the procedure
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provided with the Anti-HA-Fluorescein, High Affinity (3F10) antibody (Roche
Diagnostics).

Briefly, cells were harvested, washed and resuspended in incubation

buffer. Alternatively, for the detection of intracellular PilA, the cells were permeabilized
using toluene. Anti-HA-Fluorescein antibody was added to the cells, which were then
incubated on ice for 30 minutes, washed with incubation buffer. Images were initially
collected and recorded using an Olympus EX51 microscope with an Olympus DP70
digital camera, and subsequently with a Leica SP5 TCSII equipped with a Coherent
Chameleon multiphoton VisionII laser.

Images were further analyzed using ImageJ

1.45s software.
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Results
PAO579 has polymorphisms in algW and pilA.
Using PAO1 as a reference genome, we performed next-generation sequencing
to determine the mutation(s) (muc-23) responsible for mucoidy in PAO579
(ALOF00000000) (37). We identified 16 nonsynonymous and 15 synonymous single
nucleotide polymorphisms (SNPs) by using two critieria: more than 4X coverage and
greater than 60% frequency. (previously shown in Table 1 of Chapter 2). Consistent
with previous phenotypic observations (14, 36), we detected mutations at loci rpsL
(PA4268) and leuA (PA3792), both corresponding to previous genetic and phenotypic
markers in the parent strain PAO381 (Table 2). Further PCR sequencing revealed that
only two genes, algW (PA4446) and pilA (PA4525) contained SNPs in PAO579 when
compared to strain PAO381. Our results showed a substitution of an adenine for a
thymine at nucleotide 715 of the coding region of algW (PA4446), resulting in the
exchange of phenylalanine for isoleucine at amino acid 239 (I239F) in AlgW (Table 2).
We designated this mutation as algWI239F. We also observed three tandem nucleotide
substitutions (CT325, AG326, GA327) in pilA (PA4525) that predicted a premature
stop codon (TGA) (Table 2).

The pilA gene encodes the protein precursor that

constitutes the type-IVa pilin. Further analysis of these tandem mutations at nucleotides
352-327 confirmed a truncation in PilA from 149 to 108 amino acids (Table 2 and Figure
4). We designated this mutation as pilA108. We hypothesized that one, or both of these
mutations could be responsible for mucoidy in PAO579.
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Table 2. Summary of sequencing results for PAO579
SNP

Genome
Position

Change

SNP Position
(Gene Size)

ORF

Gene
Name

Gene Product

Protein

1

4771865

T→C

263(372)

PA4268

rpsL

30S ribosomal protein S12

K88R+

2

4251149

G→A

322(1779)

PA3792

leuA

2-isopropylmalate synthase

E108K+

3

4980548

A→T

715(1170)

PA4446

algW

DegS-like serine protease

I239F

5069207

G→A

325(450)

PA4525

pilA

Type IV fimbrial precursor

Stop

5069206

T→C

326(450)

PA4525

pilA

Type IV fimbrial precursor

Stop

5069205

C→T

327(450)

PA4525

pilA

Type IV fimbrial precursor

Stop

4
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algW and algU are required for alginate overproduction in strain PAO579.
AlgW is the first in a cascade of proteases responsible for the degradation of
MucA, (5, 38, 39). To determine if algW is required for mucoidy in PAO579, we deleted
algW and observed a decrease in alginate production and a conversion to the nonmucoid phenotype (Figure 1). Next, we cloned algW and algWI239F into the shuttle
vector pHERD20T containing the arabinose-inducible P BAD promoter (29).

The

expression of algW in trans restored mucoidy to PAO579ΔalgW (Figure 1). Similarly,
the expression algWI239 in trans restored mucoidy in PAO579, however we did not
observe a significant difference in the amount of alginate produced (Figure 1). More
importantly, algWI239F did not induce mucoidy in PAO1ΔalgW (Figure 1). These data
support AlgW being required for mucoidy in PAO579, however the I239F mutation is not
responsible for inducing mucoidy in PAO579.

While algU is reportedly not required for alginate overproduction in the strain
PAO579 (3), our data showing that AlgW is required for mucoidy, suggests that MucA
degradation, and subsequently, the release of AlgU, is occurring in PAO579. If this is
correct, expression of MucA would result in a loss of mucoidy. To test this hypothesis,
mucA was expressed from both pHERD20T and the low-copy number Ptac vector (15),
and indeed loss of mucoidy was observed (data not shown). Additionally, deletion of
algU from PAO579 resulted in a loss of mucoidy (Figure 1). Expression of algU in trans
in PAO579ΔalgU restored mucoidy (data not shown). These data suggest that AlgU is
required for alginate production in PAO579.

47

Figure 1. Alginate produced by P. aeruginosa strains PAO1, PAO381 and PAO579 mutants. All strains
were grown on PIA plates for 24h at 37°C then for 24h at room temperature. The alginate was collected and
measured using the carbazole assay. The values are reported as mean ± standard deviation of three
independent experiments. M, Mucoid; NM, Nonmucoid
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Expression of pilA108 induces mucoidy in PAO579.
Since algW

I239F

is not responsible for the induction of mucoidy, we next

examined the role of pilA108 in the regulation of alginate overproduction in PAO579.
Sequence analysis, indicates that pilA108 encodes for ~11 kDa protein. Western blot

Figure 2. Western blot analysis of PilA108 Panel A) PAO579 and PAO1 were grown at 37°C on PIA.
Cellular protein was harvested and was subjected to SDS-PAGE electrophoreses, membrane transfer, and
probed with anti-Pilin polyclonal antibody. Panel B) PAO1 cells containing pHERD20T (Vector), pHERD20T108
pilA-HA and pHERD20T-pilA -HA were grown at 37°C on PIA plates supplemented with carbenicillin and 0.1%
arabinose. Cellular protein was harvested was subjected to SDS-PAGE electrophoreses, membrane transfer,
108
and probed with anti-HA monoclonal antibody. Panel C) PAO1 pHERD20T and pHERD20T-pilA -HA was
cultured on PIA plates supplemented with carbenicillin and 0.1% arabinose. Cellular protein was harvested then
purified using high affinity anti-HA immunoprecipitation and analyzed using SDS-PAGE electrophoresis,
membrane transfer, and probed with anti-HA monoclonal antibody.

analysis using anti-PilA polyclonal antibody revealed a lack of the full length pilin protein
in PAO579 (Figure 2A).

Additionally, HA-tagged PilA108 was only detected with

Western blot analysis after immunopurification (Figure 2B and Figure 2C). Similarly,
HA-tagged PIlA108 was not detected on the cell surface of PAO1 using epifluorescent
confocal microscopy (Figure 3).
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A

B

C

D

Figure 3. Localization of PilA108. Epifluorescent confocal microscopic images
showing the localization of PilA-HA (WT) and HA-tagged PilA108 in PAO1: A)
confocal and B) epifluorescent image of PAO1 pHERD20T-pilA-HA; C) confocal
and D) epifluorescent image of PAO1 pHERD20T-pilA108-HA.
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The sequence of C-terminal of PilA108 consists of a 3 amino acid motif of
phenylalanine-threonine-phenylalanine (FTF) (Figure 3A and Figure 3B). Previously, we
reported that the C-terminal motif tryptophan-valine-phenylalanine (WVF) found on the

Figure 4. Diagram showing the predicted structure for PAO1 PilA and PAO579 PilA. A) Base pair
substitutions in the pilA gene in PAO579 result in a premature STOP codon and a truncation in the PilA protein
from 149 amino acid residues and molecular weight of 15.5 to 108 amino acid protein with a molecular weight of
11.2 kDa. PAO579 PilA has an activating domain (β2) that is responsible for the positive regulation of alginate
production which consists of a phenylalanine-threonine-phenylalanine (FTF) motif at its C-terminal. B) The
truncation of PAO579 PilA at amino acid 108 also results in the loss of the β3 and β4 antiparallel sheets, as well
as revealing the activating domain in the β2 sheet.

small periplasmic protein MucE can induce mucoidy through the activation of AlgW (31).
Based on this information, we hypothesized that the truncated pilA108 could induce
mucoidy through AlgW. We tested this hypothesis by first inactivating pilA in PAO579
through the insertion of a gentamycin cassette (PAO579pilA::aacC1). We observed a
decrease in alginate production and a conversion to the non-mucoid phenotype in
PAO579pilA::aacC1 (Figure 1). Next, we complemented these experiments by cloning
the wild-type pilA and pilA108 into pHERD20T containing the arabinose-inducible P BAD
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Expression of pilA108 increased alginate

promoter and expressed them in trans.

production inducing mucoidy in PAO579pilA::aacC1 (Figure 1), while expression of
expression of pilA wild-type did not (Figure 1). Similar results were also observed in
PAO1 (data not shown). In addition, the expression of pilA108 did not confer mucoidy in
PAO579ΔalgW, suggesting that PilA108 acts through AlgW. To confirm whether the FTFmotif found in PilA108 can induce mucoidy via AlgW, we cloned the major outer
membrane porin precursor oprF (PA1777) and oprF with the addition of the FTF motif to
its C-terminal (oprF-FTF) into pHERD20T. Next, we conjugated this construct, as well
as pHERD20T-pilA and pHERD20T-pilA108 into PAO1 and PAO1ΔalgW.

After

incubating in the presence of 0.1% arabinose, expression of oprF-FTF and
pilA108 increased alginate production and conferred mucoidy in PAO1 (Table 3).
Expression of
oprF did not induce mucoidy in PAO1, which is consistent with our previously published
results (29). Expression of pilA did not induce mucoidy in PAO1. As expected, we did
not observe any phenotypic change when pilA, pilA108, oprF, oprF-FTF were expressed
in PAO1ΔalgW. These results suggest that the FTF-motif found at the C-terminal of
PilA108 can activate mucoidy through AlgW.
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Table 3. Complementation analyses of pilA, pilA108, oprF and oprF-FTF
pilA108

oprF

PAO1

pilA
Vector
Control
NM(3.6±0.4) NM(11.7±1.6)

NM(52.7±7.1)

NM(6.3±5.8)

NM(40.8±6.8)

PAO1ΔalgW

NM(6.7±3.2) NM(4.4±4.4)

NM(5.2±3.3)

NM(4.7±1.9)

NM(7.4±1.2)

Pseudomonas strains

oprF-FTF

NM, non-mucoid; M, mucoid; pHERD20T was used in this study. All strains were grown on PIA
supplemented with 300 µg/mL carbenicillin and 0.1% arabinose and incubated at 37⁰C for 24h. The
alginate measurements for three independent experiments are represented as (Mean µg of
alginate/mL/OD600±Standard Deviation).
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pilA108 and algW are required for proteolytic degradation of MucA.
Since expression of pilA108 required algW to confer mucoidy in PAO579, we
hypothesized that the activation of alginate production was due to increased MucA
degradation. In order to test this hypothesis, we measured the degradation of MucA by

Figure 5. Western blot analysis of N-terminally tagged HA-MucA in PAO1,
PAO381, PAO579, PAO579pilA::aacC1 and PAO579ΔalgW. Shown are
representative panels of three independent experiments. All strains were
grown on PIA plates supplemented with carbenicillin and 0.1% arabinose for
24h at 37°C then for 24h at room temperature. Cell lysates were prepared and
25 µg of total protein was loaded for each sample for SDS-PAGE
electrophoresis. Following transfer, the membrane was immunoblotted with
primary rat anti-HA and secondary horseradish peroxidase-labelled goat antirat IgG. Protein levels were categorized as High MW (>20 kDa) or Low MW
(<20kDa), normalized to PAO1 pHERD20T-HA-mucA, and presented as
relative means ± standard deviations.

expressing an N-terminally HA-tagged MucA (9) via the P BAD arabinose-inducible
promoter (pHERD20T-HA-mucA) in PAO1, PAO381, PAO579, PAO579pilA::aacC1 and
PAO579ΔalgW. All strains were cultured on PIA plates supplemented with carbenicillin
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and 0.1% arabinose. Western blot analysis of PAO1 and PAO381 showed similar levels
of full length HA-MucA, although we detected greater accumulation of protein at 20 kDa
and 10 kDa in PAO381 (Figure 4, Lane 1 and 2). We detected a decrease in full length
HA-MucA and an increase in lower molecular weight products (~10 kDa) in PAO579
when compared to all other test strains (Figure 4, Lane 3). We also detected similar
amounts of full length HA-MucA in PAO579pilA::aacC1 and PAO579ΔalgW as PAO381
(Figure 4, Lane 4 and 5). These results suggest that there is an increase in MucA
degradation in PAO579 when compared to its progenitor strains PAO1 and PAO381.
Additionally, pilA108 and algW are required for increased MucA degradation in PAO579.

Increased transcriptional activity at the P algD and P algU promoters in PAO579
requires pilA108, algW, algU and rpoN.
Based on our Western blot analyses of MucA, we hypothesized that deletion of
pilA108, algW and algU would result in a decrease in transcriptional activity for the
alginate biosynthetic operon. To test this, we measured promoter activity by fusing the
entire P algD promoter to lacZ in the plasmid pLP170 (28), and performed a Miller assay
(25) . We observed a significant increase in P algD activity in PAO579 as compared to its
progenitor strains PAO1 and PAO381 (Figure 5).

We also observed a significant

decrease in P algD activity in the pilA108, algW and algU mutants in PAO579 (Figure 5).
Since the expression of the AlgU gene is auto-regulated, it is possible to indirectly
measure the release of AlgU following MucA degradation using a β-galactasidase
promoter fusion assay.

Similar to our analysis of the algD promoter, we used the

plasmid pLP170 to fuse the entire algU promoter region to lacZ, and performed a Miller
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assay. Similar to our algD promoter analysis, we observed a significant increase in
P algU activity in PAO579 compared to PAO1 and PAO381, and a significant decrease in
P algU activity in the pilA108, algW and algU mutants (Figure 5).

Figure 6. The β-galactosidase activity of the PalgD and PalgU promoter fusions was measured using the
pLP170-PalgD-lacZ and pPLP170-PalgU-lacZ reporter constructs. Each strain was on incubated at 37º C on
PIA plates supplemented with 300 ug/mL of carbenicillin. The values for the mean ± standard deviation are
shown as relative expression, and are representative of three independent experiments. Asterisks indicate
statistical significance (*P<0.05).

Additionally, we measured the effect of wild-type pilA and pilA108 expression on
merodiploid strains carrying P algD and P algU fused with the lacZ reporter gene (9) in the
presence of the shuttle vector pHERD20T, pHERD20T-pilA and pHERD20T-pilA108.
Induction of pilA108 with 0.1% arabinose, caused a significant increase in P algD activity
as compared to the vector control and wild-type pilA (Figure 6).

There was no

significant difference in P algD activity between the vector control and pilA wild-type

56

(Figure 6). A similar trend was observed when measuring the P algU promoter activity
(Figure 6).
The alternative sigma factor RpoN was reported to be required for alginate
production in PAO579 (3). Consistent with these findings, inactivation of rpoN in
PAO579 (PAO579rpoN::TcR) resulted in a significant decreases in activity at the algD

Figure 7. The β-galactosidase activity of the algD promoter and algU promoters with pilA and pilA
expressed in trans. The β-galactosidase activity was measured using the miniCTX-PalgD-lacZ and
miniCTX-PalgU-lacZ reporter constructs integrated to att site in PAO1 and pHERD20T, pHERD20T-pilA or
108
pHERD20T-pilA were conjugated using the helper plasmid pRK2013. Each strain was incubated at 37º C
on PIA plates supplemented with tetracycline, carbenicillin and 0.1% arabinose. The values for the mean
and standard deviation are shown as relative expression, and are representative of three independent
experiments. Asterisks indicate statistical significance (*P<0.01; **P<0.0005).
108

and algU promoters when compared to PAO579 (Figure 5).

Interestingly,

overexpression

mucoidy

of

rpoN

using

pHERD20T

failed

to

induce

in

PAO579pilA::aacC1 and PAO579ΔalgU, suggesting that RpoN regulates mucoidy in
PAO579 upstream of PilA and AlgU. We performed Western blot analysis to measure
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the level of RpoN in PAO1, PAO579 and PAO381 and found the level of RpoN was
comparable in these three strains (data not shown).

RpoN regulates global gene

expression of many motility genes in non-mucoid strains of P. aeruginosa (10).
Likewise, RpoN is responsible for transcription of pilA through the PilS/PilR twocomponent regulatory system (18). Deletion of rpoN from a mucoid strain resulted in
dysregulation of ~20% of the genome (8). RpoN may be involved in the expression of

B

A

Figure 8. The β-galactosidase activity of the algW promoter (A) and pilA promoter (B) was measured using the
pLP170-PalgW-lacZ and pPLP170-PpilA-lacZ reporter constructs. Each strain was incubated at 37ºC on PIA plates
supplemented with 300 ug/mL of carbenicillin. The values for the mean and standard deviation are representative
of three independent experiments. The measurement for PpilA activity is presented in log Miller Units. Asterisks
indicate statistical significance (*P<0.005; **P<0.0005).

algW (8). Expression of pilA108 in PAO579rpoN::TcR did not restore mucoidy, indicating
rpoN may have multiple roles in alginate overproduction in strain PAO579.

We

hypothesized that the inability of pilA108 to confer mucoidy in PAO579rpoN::TcR could be
due to RpoN’s role in driving transcription at both the pilA and algW promoters. We
tested this hypothesis by measuring the level of promoter activities of P pilA and P algW .
Promoter activity of P pilA and P algW between strains PAO1 and PAO381 was similar;
however, we observed a significant increase in promoter activity in PAO579 at both sites
(Figure 7A and Figure 7B). The level of promoter activity for both P pilA and P algW fell
below the threshold for detection in PAO579rpoN::TcR (Figure 7A and Figure 7B). These
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results are consistent with previous reports, stating that RpoN drives transcription of pilA
and algW in PAO579.

Collectively, our results suggest a pathway where RpoN

regulates mucoidy in PAO579 upstream of pilA108, algW and algU.
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Discussion
Generally speaking, there are two types of mucoid isolates found in CF sputum
samples: those with mutations mapped within the mucABCD cluster (1, 4, 35), and
those with undefined mutations mapped outside of the mucABCD cluster. While mucA
mutants are associated with chronic infections, it is not clear what mucoid-related
genotypes are present in those early colonizing strains that precede chronic infection.
In this study, we used whole genome sequence analysis to identify the unknown
positive regulator(s) of alginate production in P. aeruginosa strain PAO579 (muc-23), an
isogeneic derivative of PAO1. We identified three tandem point mutations in the pilA
gene resulting in a premature stop codon. These alterations cause a truncation in the
major subunit of type-IVa pilin at amino acid 108. This truncated version of PilA reveals
a C-terminal primary amino acid sequence of FTF that functions as a signal to activate
alginate overproduction through the proteolytic degradation of MucA. The transcriptional
activity at the algD and algU promoters was increased in PAO579, while inactivation of
algW, algU, rpoN and the truncated pilA caused a significant decrease in activity at
these promoters. The sigma factor RpoN regulated transcription at both the pilA and
algW promoters in PAO579.
Initially we identified a non-synonymous mutation in algW of PAO579 (algWI239F).
However, this mutation did not have an impact on AlgW activity (Figure 1). Deletion of
algW in PAO579 did result in a loss of mucoidy, however expression of algW and
algWI239F in trans from the P BAD promoter did not result in a significant difference in
alginate overproduction (Figure 1).

The amino acid substitution occurs in a non-

conserved region of the L2 loop (5) and this may explain why we did not observe any
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significant difference in the amount of alginate produced. Collectively, these results
indicate that algWI239F is not the positive regulator involved in activating alginate
overproduction.

However, the requirement of AlgW for mucoidy does implicate the

Figure 9. Schematic diagram summarizing the induction of alginate production and mucoid
conversion by PilA108 in P. aeruginosa strain PAO579. The sigma factor RpoN is required for
108
108
transcription of pilA and algW. PilA is transported to the periplasm where it activates the periplasmic
protease AlgW which proteolytically degrades the anti-sigma factor MucA releasing the sequestered sigma
factor AlgU. AlgU drives transcription of the alginate biosynthetic operon via the algD promoter.

release of AlgU due to proteolytic degradation of MucA. Western blot analysis of the
HA-MucA confirmed an increase in lower molecular weight products in PAO579 as
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compared to PAO1, PAO381, PAO579pilA::aacC1 and PAO579ΔalgW (Figure 5),
indicating increased MucA degradation in PAO579.
We observed that the deletion of algU resulted in a loss of mucoidy in PAO579
(Figure 1). In Boucher et. al., RpoN was shown to be involved in driving transcription at
P algD (3). In this same study algU was inactivated by an insertion of a tetracycline
resistance cassette and observed to not be essential for the mucoid phenotype of
PAO579 (3).

In our study, since AlgW was required for the mucoid phenotype of

PAO579, degradation of MucA, and transcriptional activity at the P algD promoter (Figure
1, Figure 4 and Figure 5), we hypothesized that AlgU was most likely required for the
mucoid phenotype of PAO579.

We then in-frame deleted algU from PAO579 and

observed this strain to be non-mucoid (Figure 1). We were also able to complement
this mutated strain by expressing algU in trans and observed a return to the mucoid
phenotype (data not shown). The essential difference between our present work and
the Boucher et. al. study is the complete deletion of algU from PAO579 in our study.
Although our data argues that algU is required, it also confirms that RpoN is required for
mucoidy in PAO579 (Figure 6 and 8).

However, overexpression of RpoN in

PAO579pilA::aacC1 and PAO579ΔalgU did not confer mucoidy.

Additionally, we

observed that rpoN may be regulating alginate production upstream of AlgU through
controlling expression of algW and pilA (Figure 8). Collectively these data suggest a
pathway where RpoN acts upstream of pilA108 and algU in regulating mucoidy in
PAO579, as illustrated in Figure 9.

RpoN drives transcription of algW and pilA108;

PilA108 then activates AlgW to begin proteolytic degradation of MucA. Upon release,
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AlgU drive transcription of the alginate biosynthetic and algUmucABCD operons via the
P algD and P algU , respectively.
The pilA gene encodes the Type-IV pilin precursor that is responsible for
adhesion to respiratory epithelial cells (11), as well as surface translocation or twitching
motility (24).

Two missense mutations in pilA of Myxococcus xanthus can cause

membrane accumulation of pili, resulting in a decrease in exopolysaccharide production
(41). Similarly, our current study found three tandem missense mutations in pilA that
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Figure 10. Basic Local Alignment Search Tool (BLAST) for the C-terminal of the PilA. The red arrow identifies the
location of the truncation revealing the phenylalanine-threonine-phenylalanine (FTF) motif found in PAO579. The black arrows
identify clinical isolates containing the same internal motif with NCBI accession GI number and strain name.

affect exopolysaccharide production; however in contrast to the Yang et al study (41),
we observed an overproduction in alginate (Figure 1).

Hypermutations have been

shown to occur in P. aeruginosa strains with those mutations typically associated with
mutS gene in the DNA mismatch repair system (27). Additionally, alterations in the
mutL and uvrD have also been shown to result in a mutator phenotype (26). However,
we did not detect any polymorphisms at these loci, suggesting that the frequency at
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which three tandem point mutations may occur is quite low. Although the C-termini of
pilin displays a high diversity, those found in CF isolates tend to cluster together into
one phylogenic group (20).

Through BLAST searches, we identified 6 CF isolates

containing an internal FTF motif (Figure 10).

It is known that mucoid mutants are

selected for in the CF lung. Our study suggests that mutations can arise in envelope
proteins, such as pilA, and induce alginate overproduction. Since regulated proteolysis
is controlled by the AlgW protease and envelope proteins, we wonder if a treatment
strategy targeting these proteins could block alginate overproduction and allow for
better clearance of chronic P. aeruginosa infections.
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Chapter 4 Overview and Rationale
In chapter 3, I determined that a series of single nucleotide polymorphism in the
pilA gene result in the overproduction of alginate in PAO579.

However, inhibiting

mucoidy and biofilm formation is of particular importance regarding the prevention of
chronic respiratory infections in individuals afflicted with cystic fibrosis.
In this chapter, I change the trajectory of our study to target novel genetic loci
that can suppress alginate overproduction in P. aeruginosa strains possessing a wildtype MucA. To do so, I used whole-genome complementation coupled with in vitro
transposon mutagenesis to identify an uncharacterized locus which suppresses
mucoidy in the model strain PAO579.

I also explore its efficacy and specificity in

suppressing mucoidy in a variety of P. aeruginosa strains.
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Abstract
In this study, we used whole genome complementation of a PAO1 cosmid library,
coupled with in vitro transposon mutagenesis, to identify a gene locus (PA1494)
encoding a novel inhibitor of alginate overproduction in Pseudomonas aeruginosa
strains possessing a wild-type mucA.

Keywords: Pseudomonas aeruginosa, alginate, biofilm, inhibitor, PA1494
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Introduction
Cystic fibrosis (CF) is autosomal recessive disorder that afflicts approximately
70,000 individuals throughout the world. CF can have serious effects on the pulmonary,
gastrointestinal and cardiovascular organ systems. This is due to the accumulation of
mucus at the surface of epithelial cells. In the lungs, the accumulated mucus causes a
greater susceptibility to bacterial infection, with the most common pathogen being
Gram-negative bacterium Pseudomonas aeruginosa (9). This bacterium establishes a
chronic infection in individuals afflicted with CF, through the formation of a mucoid
biofilm, which is facilitated by the overproduction of an exopolysaccharide called
alginate (9).
Alginate overproduction is achieved through increased transcription of the
alginate biosynthetic operon at the algD promoter (7).

Regulation of alginate

overproduction primarily involves the alternative sigma factor AlgU (AlgT, σ22) and its
cognate anti-sigma factor, MucA (18, 19). Typically, in environmental isolates of P.
aeruginosa, AlgU is sequestered by MucA to the inner membrane (20, 27). However,
with a loss of MucA, AlgU is free to regulate transcription at the algD promoter (18, 32).
Previous reports have determined the role of AlgW, a DegS-like serine protease, as the
first in a series of proteases to degrade MucA (2, 25, 31). Transcription of the alginate
operon can also be dependent on the AlgK-AlgX-MucD multiprotein complex (11).
Overexpression of MucE (PA4033) induces mucoidy through the regulated proteolysis
of MucA (25). Additionally, we found that the truncation of the type IV precursor protein
pilA can also induce mucoid through the regulated proteolysis of MucA in strain
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PAO579 (29). Importantly, P. aeruginosa isolates initially colonizing the CF lung are
typically nonmucoid, environmental strains.
In this study, we used our knowledge of pathways for overproduction of alginate
in the P. aeruginosa strain PAO579 to identify additional regulators of alginate
synthesis. Preventing the overproduction of alginate (26), and more specifically
inhibiting the regulated proteolytic degradation of MucA (4), is an attractive strategy to
prevent the establishment of chronic P. aeruginosa infections. To investigate this
possibility, we employed whole-genome complementation coupled with in vitro
transposon mutagenesis to identify new genetic loci that can inhibit alginate
overproduction in P. aeruginosa strains with a wild-type mucA.
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Materials and Methods
Bacterial strains and growth conditions. All pertinent information regarding bacterial
strains and plasmids used in this study are provided in Table 1. P. aeruginosa and E.
coli strains were grown at 37°C in Lennox broth (LB), on LB agar, or Pseudomonas
Isolation Agar (PIA). When indicated, the media was supplemented with 300 µg/mL
carbenicillin, 200 µg/mL gentamycin, 200 µg/mL tetracycline and L-arabinose for P.
aeruginosa strains, and 100 µg/mL carbenicillin, 15 µg/mL gentamycin, 10 µg/mL
tetracycline and 40 µg/mL kanamycin for E. coli strains.

MTP complementation and in vitro mutagenesis. A PAO1-derived minimal tiling
pathway (MTP) genomic cosmid library was conjugated into PAO579 using the helper
plasmid pRK2013, and screened for the ability to complement mucoidy. MTP cosmids
that complemented mucoidy were isolated using Qiagen Maxi Prep Kit (Qiagen). In
vitro transposon-mediated mutagenesis of the complementing cosmid was performed
using EZ::TN <KAN-2> insertion kit (Epicentre).

To construct a mutant library,

transposon-inserted cosmids were transformed into E. coli DH5α and cultured on LB
plates with kanamycin. The mutant library was conjugated en masse into PAO579 and
cultured on PIA with tetracycline overnight at 37°C. Cosmids were screened for loss of
complementation (i.e.; return to mucoidy).

Plasmid construction and complementation. Standard recombinant DNA cloning
techniques were used in the construction of all plasmids used in this study (28). Briefly,
oligonucleotide primers were designed based on PAO1 sequence information and

75

synthesized by Eurofin MWG Operon.

PCR amplifications were done using

EasyStart™ Micro 50 PCR Mix-in-a-Tube (Molecular BioProducts) and Taq DNA
Polymerase (New England BioLabs) was used for PCR amplification.

The pCR®4-

TOPO® Vector (Invitrogen, Inc.) was used as an intermediary before ligation into the
target vector. Plasmids were isolated using the QIAprep® Spin Miniprep Kit (Qiagen
Sciences). All cloning constructs were sequenced to confirm the absence of mutations.
Completed plasmids were tri-parentally conjugated into target P. aeuginosa strains
using E. coli containing the helper plasmid pRK2013 (8).

β-galactosidase activity assay.

PAO1 or PAO579 carrying the chromosomal

integration vector miniCTX-P algD -lacZ and either pHERD20T, pHERD20T-muiA or
pHERD20T-muiAΔN22 were cultured at 37°C on three PIA plates supplemented with
300 µg/mL carbenicillin and 0.1% arabinose.

Bacterial cells were harvested,

resuspended in PBS and the OD 600 was recorded. The cells were permeabilized using
toluene, and β-galactosidase activity was measured with results calculated and reported
in Miller Units (21). One Miller Unit equivalent to 1000 X (A 420 /-1.75 X A 550 /OD 600 mL1

min-1). The reported values represent an average of three independent experiments

with standard deviation.

Student’s t test was performed to determine statistical

significance.
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Table 1. Bacterial strains and plasmids used in this study.
Strain, Plasmid

Genotype, phenotype, description

Reference

E. coli
DH5α derivative

Invitrogen

PAO1

algU+mucA+; nonmucoid

P. Phibbs*

PAO579

algU+mucA+muc-23; mucoid

J. Govan**

PAO1-VE2

algU+mucA+, P GM -mucE (PA4033); mucoid

(25)

PAO1-VE19

algU+mucA+, mucD::aacC1 (PA0766); mucoid

(25)

C4700m

algU+mucA+; clinical isolate; mucoid

D. Speert***

C7447m

algU+mucA+; clinical isolate; mucoid

D. Speert***

pCR4-TOPO

3.9-kb, ApR, KmR; TA cloning vector

Invitrogen

pRK2013

KmR, Tra Mob ColE1

(8)

pUCP20T P lac replaced by 1.3-kb AflII-EcoRI fragment of araC-P BAD

(23)

TOP10
P. aeruginosa

Plasmids

pHERD20T
cassette
pHERD20T-muiA

muiA (PA1494) from PAO1 in pHERD20T; EcoRI/HindIII

pHERD20T-muiA-

This study
This study

muiA (PA1494) from PAO1 in pHERD20T; EcoRI/HindIII
HA
pHERD20T-

muiA (PA1494) from PAO1 in pHERD20T with a deletion of the N-

muiAΔN22

terminal signal sequence; EcoRI/HindIII

miniCTX-lacZ
miniCTX-P algD lacZ
pEX100T-NotI

pEX100T-ΔmuiA

Gene delivery system used to fuse target genes to lacZ and integrate
onto the chromosome at the CTX phage att site in P. aeruginosa, TcR
Complete P algD promoter (1,525 bp upstream of ATG) HindIII/BamHI
in miniCTX-lacZ
Pseudomonas suicide vector with NotI restriction site fuse into SmaI
of pEX100T, sacB, oriT, CbR
1.0-kb fragment flanking the muiA (PA1494) gene ligated into
pEX100T-NotI with in-frame deletion of muiA

This study

(12)
(6)
(6)
(25)

*P. Phibbs, East Carolina University, Greenville, NC, USA; **J. Govan, University of Edinburgh, Scotland,
UK; ***D. Speert, University of British Columbia, Vancouver, B.C., Canada
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Cell fractionation and protein analyses. P. aeruginosa strain PAO579 containing the
pHERD20T-muiA-HA was cultured at 37°C on PIA supplemented 300 µg/mL of
carbenicillin and 0.1% arabinose. Cells were collected and whole cell lysates were
prepared using the ProteaPrep Cell Lysis Kit (Protea Biosciences). Periplasmic proteins
were harvested using the Epicentre Periplasting Kit (Epicentre).

Outer membrane

proteins were collected and isolated using 2% sarkosyl with 2 mM PMSF, sonication
and ultracentrifugation as previously published (5). The total protein content for each
fraction was quantified using D c Assay (Bio-Rad). Protein samples (25 µg) were boiled
for 10 min in Tricine Sample Buffer (Bio-Rad) and electrophoresed on a 12.5% TrisGlycine gel (Bio-Rad). Samples were then electro-blotted onto a nitrocellulose transfer
membrane (GE Healthcare). The membrane was blocked using 3% skim milk/PBS.
Rat monoclonal antibody for hemagglutinin (Roche Diagnostics) was used as primary
antibody. Horseradish peroxidase-labeled goat anti-rat IgG was used as secondary
antibody.

Primary and secondary antibodies were diluted in 3% skim milk/PBS to

1:5000 and 1:10,000, respectively.

Western blot results were imaged using ECL

Advance Western Blotting Detection Kit (Amersham; GE Healthcare) and UVP
BioImagining Systems.

Alginate assay.

Alginate was measured using the previously published carbazole

reaction (16). Bacterial strains were streaked in triplicate on PIA supplemented with
antibiotics and/or L-arabinose when appropriate, and incubated at 37° C for 24 hrs. The
bacterial cells were collected and the OD 600 was recorded. The amount of uronic acid
was measured and compared to an alginate standard curve made with D-mannuronic
78

acid lactone (Sigma-Aldrich) in the range 0 to 100 μg/mL.

The reported values

represent an average of three independent experiments with standard deviation.
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Results and Discussion
PA1494 encodes a novel inhibitor of alginate overproduction.
Alginate overproduction in P. aeruginosa strain PAO579 (muc-23), a derivative of
PAO1, is caused by the release of AlgU from MucA by regulated intramembrane
proteolysis (29, 30).

This regulated intramembrane proteolysis is initiated by the
activation of the protease
AlgW by a truncated type-IV
pili (PilA108) (29). To identify

transposase

sequence Tn flanking
regions & identify
corresponding
mucoidy inhibitors

+

Tn
TM

EZ::TN

inactive complement
restores biofilm

<KAN-2>
Tn

overproduction

in

P.

aeruginosa strains with a

nonmucoid

+

novel inhibitors of alginate

wild-type mucA, a PAO1Tn

nonmucoid
MTP
cosmids

derived, minimal tiling path

Tn

(MTP)

mucoid
in vitro random
transposon mutagenesis

genomic

cosmid

library (13) was conjugated

Tn

nonmucoid

into

Figure 1. Identification of PA1494 as a novel inhibitor of alginate
overproduction. MTP87 cosmid was subjected to in vitro transposon
mutagenesis to generate random gene knockouts. Shown in the inset are
PAO579 (muc-23) exconjugants carrying cosmid MTP87 randomly
mutagenized with an EZ::TN transposon (Epicentre), selected on a PIA
plate supplemented with the appropriate antibiotic, and incubated at 37°C
for 48h.

PAO579

(10).

The

cosmid MTP87 completely
suppressed

alginate

overproduction in PAO579

(data not shown). MTP87 covers a region of 22,757 bp from the genome of PAO1 (start:
1,618,021; end: 1,640,777). To identify the exact gene within this cosmid responsible
for the multi-copy suppression of alginate overproduction, MTP87 was subjected to
random transposon-mediated in vitro mutagenesis, and the mutated cosmids were then
80

conjugated en masse into PAO579 and screened for alginate overproduction (Figure 1).
We observed the presence of alginate overproducing clones indicating a transposonmediated inactivation of a specific inhibitory gene within cosmid MTP87. PCR and

SalI
SalI

SalI
EcoRV

NcoI
0.0kb

EcoRI
HindIII
SmaI

1.0kb

PA1495

MinA
MuiA
PA
PA
NOS
NOS
BJ
BJ
RB
RC
CE
CE
Consensus
Consensus

muiA (PA1494)

2.0kb

EZ::TN
1 23

XhoI

EcoRI
KpnI
NotI
EcoRI
SalI

NcoI

SalI
BglI

3.0kb

cysP (PA1493)

WQPTYDARLRDGAKT----IELTYQGLVRQSSGEDWTDVDLTLSTARPALGG-NVPRLN
WTPLYDLRLNSTNKT----VNLSYLAEVNQNTGEDWLDVALTLSTAKPGLGT-LPPKLK
WLPLYDARLDTGAKDRKPQLELVRRAEITQSTGEDWSNITLGVSTVRVSRGG-SAPELG
WAPSYDARLDSAAGS----LALDRFVSVHQASGEDWRGVALVLSTARPSERT-DPSQMW
WTPFYDIRVTAGVEA---EMHVTYFGKVRQYSGEDWKTVPLVLSTARPAHGVKQLPKLGA
* * ** *:
: :
: * :**** : * :**.: .
..:

Figure 2. Characterization of PA1494. Restriction map, gene organization and Tn insertion in the muiA
gene. Homology of MuiA with its orthologs. Shown are the most homologous regions (1, 2 and 3): R.
capsulatus (RC; ORF1654; 534 aa), B. japonicum (BJ; CAC38742; 560 aa), Nostoc sp. (NOS; NP_484904; 545
aa), and C. elegans (CE; NP_500427; 556 aa). A single Tn insertion occurred before regions 1, 2 and 3.

sequence analysis of the mutagenized MTP87 confirmed a single transposon insertion
in open reading frame PA1494. This gene is up-regulated when P. aeruginosa is
exposed to azithromycin (15, 22) and hydrogen peroxide (3). However, since PA1494
belongs to a class of unclassified/hypothetical genes, and its exact function is unknown,
we refer to PA1494 as mucoidy inhibitor gene A, or muiA.
The muiA gene is predicted to encode a polypeptide of 551 amino acids with a
predicted molecular mass of 61 kDa and an isoelectric point (pI) of 5.5. Located
immediately downstream is the E. coli periplasmic sulfate-binding ortholog gene (cysP:
PA1493). The muiA gene uses GTG as a start codon with a typical type-I signal
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sequence encoding 22 amino acids (NH 2 -MNRLAASPLLFAGLFASAPLLA-COOH) (17),
and previous proteomic analysis detected MuiA in the periplasm of PAO1 (14). Through
BLAST analysis, we determined that MuiA is highly conserved amongst other P.
aeruginosa strains; however no orthologs were identified in E. coli species, or other
Pseudomonads. MuiA orthologs were found in other organisms including Rhodobacter
capsulatus,
japonicum,

Bradyrhizobium
Nostoc

sp.,

and

Caenorhabditis elegans (Figure 2).
These orthologs are all of similar
size ranging from 530 to 560
amino acids in length, and are
classified

as

hypothetical proteins.

conserved

Figure 3. Western blot analysis and localization of
MuiA. PAO579 pHERD20T-muiA-HA was cultured on PIA
supplemented with carbenicillin and 0.1% arabinose. Shown
is a representative panels from three independent
experiments in which 25 μg total protein for whole cell lysate
(Lane 1), periplasmic (Lane 2) and outer membrane (Lane 3)
extracts were loaded on a 12.5% Tris-Glycine gel,
transferred to a nitrocellulose membrane, and probed with
anti-HA antibody.

An internal region of MuiA (232-274aa) displayed 3 highly

conserved regions. In addition, the transposon insertion in MTP87 was located 15 bps
in front of these conserved domains (Figure 2). Additionally, using cell fractionation and
Western blot analysis, we confirmed the results presented in the previous study by
Imperi et al. (14) by detecting the presence of MuiA in the periplasm (Figure 3).

Expression of muiA suppresses alginate overproduction.
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In order to confirm whether muiA is responsible for suppressing alginate
overproduction, we used standard molecular techniques (28) to clone muiA into the
shuttle vector pHERD20T that contains the P BAD arabinose inducible promoter (23).
PAO1 pHERD20T (vector control), PAO579 pHERD20T and PAO579 pHERD20T-muiA
were cultured on PIA supplemented with carbenicillin and 0.1% arabinose, and the

*

Figure 4. MuiA suppresses alginate overproduction. PAO1 pHERD20T, PAO579
pHERD20T (vector control), PAO579 pHERD20T-muiA (wild-type muiA) and PAO579
pHERD20T-muiAΔN22 (deletion of N terminal signal sequence) were grown on PIA
plates supplemented with carbenicillin and 0.1% arabinose for 24h at 37°C then for 24h
at room temperature. The alginate was collected and measured using the standard
carbazole assay. The unit of measurement used is µg of alginate/mL/OD600, and the
values are representative of three independent experiments. Statistical significance
was determine using the Student’s t-test in comparison with PAO579 (*P<0.05).

amount of alginate was measured using the standard carbazole assay (16). When
compared to the PAO1 and the vector control, there was a decrease in alginate
overproduction when muiA was expressed in trans (Figure 4).

Additionally, we

observed that pHERD20T-muiA can suppress mucoidy even in the absence of
arabinose on PIA, suggesting that the basal expression from pHERD20T-muiA was
sufficient for the suppression. Removal of the N-terminal signal sequence (pHERD20T-
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muiAΔN22) abrogated MuiA’s ability to suppress alginate overproduction in PAO579
(Figure 4).

An in-frame deletion of muiA in strain PAO1 did not result in alginate

overproduction, suggesting that MuiA does not play a central role in alginate regulation
(data not shown).

Thus, MuiA likely suppresses alginate overproduction after

localization to the periplasm, and also functions as a multi-copy suppressor for alginate
overproduction in PAO579.

Expression of muiA decreases P algD transcriptional activity.
Alginate overproduction in PAO579 has been reported to be due to increased
transcriptional activity at the P algD promoter site of the alginate biosynthetic operon (1,
29). To test the effect of expression of muiA on P algD activity, we used PAO1 and
PAO579 merodiploid strains (generated via miniCTX-P algD -lacZ) that carry a
chromosomal copy of the algD promoter fused with a reporter gene, lacZ. Next, we
conjugated pHERD20T (vector control) pHERD20T-muiA and pHERD20T-muiAΔN22
into the PAO1 or PAO579 miniCTX-P algD -lacZ, and cultured them on PIA plates
supplemented with carbenicillin, tetracycline and 0.1% arabinose. We measured the
transcriptional activity of the P algD promoter using the Miller Assay (21). As expected,
the level of transcriptional activity in PAO579 pHERD20T was significantly higher than
that in PAO1 (Figure 5). The activity at P algD decreased when pHERD20T-muiA was
expressed in trans in PAO579 (Figure 5).

Additionally, expression of pHERD20T-

muiAΔN22 did not result in a decrease in P algD activity in PAO579 (Figure 5). Based on
these results, we conclude that expression of muiA suppresses transcriptional activity at
the alginate biosynthetic operon at the algD promoter.
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Figure 5. MuiA suppresses transcription activity at the PalgD promoter. The βgalactosidase activity of the algD promoter was measured using PAO1 and PAO579 miniCTXPalgD-lacZ with pHERD20T, pHERD20T-muiA or pHERD20T-muiAΔN22. All strains were
incubated at 37º C on PIA plates supplemented with tetracycline, carbenicillin and 0.1%
arabinose. The values for the mean and standard deviation Miller Units (One Miller Unit=1000
-1
-1
X (A420/-1.75 X A550 /OD600 mL min )) are shown as relative expression as compared to
PAO1, and are representative of three independent experiments. Statistical significance was
determine using the Student’s t-test in comparison to PAO579 (*P<0.05).

Expression of muiA suppresses alginate overproduction only in strains with a
wild-type MucA.
To determine the overall robustness, and also elucidate the possible mechanism
by which MuiA suppresses alginate overproduction, we conjugated pHERD20T-muiA
into a variety of laboratory and clinical strains. Expression of muiA in trans suppressed
alginate overproduction in PAO1-VE2 (Table 2). PAO1-VE2 is a derivative of PAO1,
and overproduces alginate due to activation of AlgW by MucE, a small envelope protein
(2, 25). When muiA was expression in trans it suppressed alginate overproduction in
clinical strains possessing a wild-type MucA (C7447m and C4700m), but muiA was
unable to suppress alginate overproduction in the PAO1-derived, mucA25 strain,
PAO581 (Table 2).

PAO581 carries a truncated MucA25 protein which lacks the
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transmembrane domain of the wild-type MucA, suggesting that MucA25 is likely
localized in the cytoplasm (24).

Additionally, expression of muiA did not suppress

alginate overproduction in the strain PDO300 (Table 2). PDO300 carries a truncated
MucA22 protein. Interestingly, expression of muiA did not complement mucoidy in the
PAO1-VE19 (Table 2). This strain is mucoid due the inactivation of the serine protease
MucD (PA0766).

The relationship between MuiA and MucD is explored further in

Chapter 5. Importantly none of the strains examined in this study, aside from PAO579,
have three tandem mutations resulting in a truncation of type IV pili. Collectively, these
data suggest that MuiA’s ability to suppress alginate overproduction is not unique to
PAO579; however it is only effective at suppressing alginate overproduction in strains
with a wild-type MucA.
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Table 2. MuiA-mediated suppression of alginate overproduction in laboratory and
clinical strains
Vector Controla
muiAb
Strains
Genotype
Laboratory Strains
mucA+

NM(16.0±4.4)*

NM(6.8±1.3)

PAO579

mucA+; muc23

M(56.6±7.4)*

NM(9.0±1.2)*

PAO581

mucA25

M(102.2±12.5)

M(111.6±9.3)

PAO1-VE2

mucA+; P Gm -mucE

M(76.3±8.3)

NM(12.2±3.4)

PAO1-VE19

mucA+; mucD::aacC1

M(32.6±6.8)

M(40.1±4.3)

PAO1 mucA22

M(81.8±9.5)

M(76.0±9.6)

C4700m

mucA+

M(66.7±20.1)

NM(17.2±2.5)

C7447m

mucA+

M(71.8±3.3)

NM(18.2±1.8)

PAO1

PDO300
CF Clinical Strains

All strains were conjugated with pHERD20Ta or pHERD20T-muiAb, using E. coli pRK2013
and cultured on PIA supplemented with 300 µg/mL of carbenicillin and 0.1% arabinose and
incubated at 37⁰C for 24h, then at room temperature for 24h. The alginate measurements for
three independent experiments are represented as (Mean±Standard Deviation).
*-as
presented in Figure 4.

87

Summary
In summary, we coupled whole genome complementation of a PAO1 cosmid
library and in vitro transposon mutagenesis to identify a genetic loci, PA1494 (muiA), as
a novel inhibitor of alginate overproduction in P. aeruginosa strains with a wild-type

Figure 6. Schematic diagram illustrating the suppression of alginate overproduction by
MuiA. The sigma factor AlgU drives transcription of the alginate biosynthetic operon at the PalgD
promoter following regulated intramembrane proteolysis of MucA in P. aeruginosa strains PAO579
and PAO1-VE2 (2, 25, 29). Expression of MuiA suppresses alginate overproduction in these strains
following localization to the periplasm.

mucA. Also, expression of muiA in trans resulted in a decrease in alginate production,
as well as transcriptional activity at the P algD promoter. As outlined in Figure 6, we
propose that expression of muiA suppresses alginate overproduction via the periplasm
in P. aeruginosa strains PAO579, PAO1-VE2, and clinical strains with a wild-type MucA.

88

Nucleotide sequence accession numbers. The GenBank accession number for P.
aeruginosa strain PAO579 mucoidy inhibitor A (muiA) gene is AF226874.
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Chapter 5 Overview and Rationale
In chapter 4, I discovered that expression of gene locus PA1494 (muiA) can only
inhibit mucoidy in P. aeruginosa strains possessing a wild-type MucA. Additionally, I
observed that MuiA required the periplasmic chaperone protease MucD to suppress
mucoidy. Based on these results, I wanted to determine the molecular mechanism by
which MuiA suppresses mucoidy, as well as MucD’s role in this regulation.
In this chapter, I used Western blot and protease analyses to examine the
relationship between MuiA and MucD. Additionally, I compared the proteomic profiles of
two different mucoid strains expressing MuiA in trans to identify potential effector
proteins.
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Abstract
In Chapter 4, we reported that the expression of the gene locus PA1494 (muiA)
did not suppress alginate overproduction in the PAO1-VE19, a mucoid mutant of PAO1
containing a transposon-inactivated mucD.

The protein enoded by mucD is a

periplasmic serine protease classified as a negative regulator of AlgU and alginate
production.

Inactivation of MucD bypasses the requirement of AlgW for alginate

overproduction. In this chapter, I present my work that further explored the relationship
between the newly identified alginate regulator, MuiA, and the periplasmic protease
MucD. Western blot analysis of MucD showed an increase in low molecular weight
products in PAO579 when compared to PAO1, and expression of muiA in trans reduced
the amount of these low molecular weight products to the level found in PAO1.
Additionally, we observed a low amount of low molecular weight products of MucD in
PAO579ΔalgU.

Zymogram protease analysis showed an increase in periplasmic

proteolytic activity in PAO579 as compared to PAO1 at the molecular weight of ~50
kDa.

Moreover, we observed a decrease in periplasmic proteolytic activity at a

molecular weight of ~50 kDa when muiA was expressed in trans.

Using iTRAQ

analysis, we observed the down-regulation of three proteins common between PAO579
and PAO1-VE2 when muiA was expressed in trans. These data indicate a relationship
between the expression of MuiA, MucD and periplasmic protease activity, as well as
identifies three potential downstream effectors of MuiA: elongation factor-Tu (PA4277),
PasP (PA0423) and trigger factor (tig, PA1800).
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Introduction
The overproduction of alginate, or mucoidy, is a virulence factor commonly
associated with the development of a biofilm, and the establishment of a chronic P.
aeruginosa infection in individuals with cystic fibrosis (9).

There is considerable

research identifying many of the key proteins involved in the regulation of alginate
production. Most notable are the proteins AlgU, AlgW, and MucA. The production of
alginate is primarily controlled by the sigma factor known as AlgU, whose activity is
modulated by its cognate anti-sigma factor MucA (15, 16, 20). AlgW is a periplasmic
protease localized in the inner leaflet of the cytoplasmic membrane, and acts on the Cterminus of MucA. The accumulation of periplasmic or outer membrane proteins, as
well as environmental stressors, can activate AlgW to initiate proteolytic cleavage of
MucA, thereby releasing AlgU to up-regulate the expression of the alginate biosynthetic
operon (2, 19, 23). In Chapters 3 and 4, we presented evidence that the accumulation
of type-IV pili induces mucoidy through an AlgW-dependent pathway in the model strain
PAO579 (22). Additionally, expression of the gene locus PA1494, referred to as muiA,
suppressed mucoidy in laboratory and clinical strains of P. aeruginosa possessing a
wild-type MucA.
The suppression of mucoidy by the expression of muiA in trans required the
periplasmic serine protease MucD (Chapter 4, Table 2). MucD is a homolog of the
periplasmic serine protease DegP found in E. coli, and negatively regulates alginate
production (1). Similar to the role of DegP in E. coli, expression of MucD can remove
misfolded or accumulated periplasmic proteins that may activate alginate production,
such as the small envelope protein MucE (19). Boucher et al. and Qiu et al. also
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observed that inactivation of MucD in PAO1 resulted in a conversion to mucoidy (1, 19).
Interestingly, inactivation of MucD resulted in the degradation of MucA independent of
the periplasmic protease AlgW, and is dependent on the site-2 protease MucP (6). The
cytoplasmic chaperone protease complex ClpXP, in conjunction with Trigger Factor
(tig), is required for the induction of mucoidy by degrading the cytoplasmic portion of
MucA (18).
In this study, we used Western blot of analysis to explore the relationship
between expression of MuiA and MucD. Expression of muiA from arabinose-inducible
vector pHERD20T in PAO579 caused a decrease in the amount of lower molecular
weight products of MucD.

Similarly, a decrease in the amount of lower molecular

weight products of MucD was observed in PAO579ΔalgU.

Based on these

observations, we examined the proteolytic activity in the periplasm of PAO579 using
zymogram protease gel analysis.

We observed an increase in protease activity in

PAO579 at a molecular weight of 50 kDa in PAO579 compared to PAO1. Expression of
muiA in trans resulted in a decrease in 50 kDa proteolytic activity to below detectable
levels. Additionally, a comparative proteomic analysis of PAO579 and PAO1-VE2 with
and without expression of muiA in trans identified EF-Tu (PA4277), Trigger Factor
(PA1800) and the extracellular protease PasP (PA0423) as potential effectors of MuiA.
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Materials and Methods
Bacterial strains and growth conditions. Information regarding the bacterial strains
and plasmids used in this study are provided in Table 1. P. aeruginosa strains were
grown at 37°C on Pseudomonas Isolation Agar (PIA). When indicated, the media was
supplemented with 300 µg/mL carbenicillin and 0.1% L-arabinose.
Western blot analysis of MucD. Bacterial strains were grown overnight at 37°C on
PIA plates supplemented with carbenicillin and L-arabinose. Cells were harvested and
whole cell lysates were prepared using the ProteaPrep Cell Lysis Kit (Protea
Biosciences), and the total protein content was quantified using D c Assay (Bio-Rad).
Protein samples (50 μg) were boiled for 10 min in Tris-Glycine Sample Buffer (Bio-Rad)
and electrophoresed on a 12.5% Tris-Glycine polyacrylamide gel. Samples were then
transferred to a nitrocellulose membrane and blocked using 3% skim milk/PBS. AntiMucD monoclonal antibody was used as the primary antibody, and horseradish
peroxidase-labelled goat anti-mouse IgG was used as the secondary antibody. Primary
and secondary antibodies were diluted in 3% skim milk/PBS to 1:10,000 and 1:10,000,
respectively. Western blot results were imaged using ECL Advance Western Blotting
Detection Kit (Amersham; GE Healthcare) and UVP BioImagining Systems. Blots were
stripped using 62.5 mM Tris-HCl pH 6.8, 2% SDS, 100 mM β-mercaptoethanol for 10
minutes at 40°C, and re-probed using anti-RNAPα and horseradish peroxidase-labelled
goat anti-mouse IgG.
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Table 1. Bacterial strains and plasmids used in this study.
Strain, Plasmid

Genotype, phenotype, description

Reference

E. coli
DH5α derivative

Invitrogen

PAO1

algU+mucA+; nonmucoid

P. Phibbs*

PAO579

algU+mucA+pilA108(muc23); mucoid

J. Govan**

PAO1-VE2

algU+mucA+, P GM -mucE (PA4033); mucoid

(19)

PAO1-VE19

algU+mucA+, mucD::aacC1 (PA0766); mucoid

(19)

TOP10
P. aeruginosa

Plasmids
pCR4-TOPO

3.9-kb, ApR, KmR; TA cloning vector

pRK2013

KmR, Tra Mob ColE1

(7)

pUCP20T P lac replaced by 1.3-kb AflII-EcoRI fragment of araC-P BAD

(17)

Invitrogen

pHERD20T
cassette
pUCP26T P lac replaced by 1.3-kb AflII-EcoRI fragment of araC-P BAD

(17)

pHERD26T
cassette
pHERD20T-muiA

muiA (PA1494) from PAO1 in pHERD20T; EcoRI/HindIII

This study

pHERD26T-muiA

muiA (PA1494) from PAO1 in pHERD26T; EcoRI/HindIII

This study

*P. Phibbs, East Carolina University, Greenville, NC, USA
**J. Govan, University of Edinburgh, Scotland, UK
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Protein isolation and zymogram protease analysis.

P. aeruginosa strains PAO1

pHERD20T, PAO579 pHERD20T, PAO579ΔalgU and PAO579 pHERD20T-muiA were
cultured at 37°C on PIA plates supplemented 300 µg/mL of carbenicillin and 0.1%
arabinose. Cells were collected and the periplasmic proteins were harvested using the
Epicentre Periplasting Kit (Epicentre). Electrophoresis was performed as previously
described, but with 12.5% polyacrylamide gel containing zymogen and casein (BioRad). Following electrophoresis, gels were incubated in renaturing solution (2.5% Triton
X-100) for 30 minutes at room temperature, then at 37⁰C for overnight in development
solution (50 mM Tris, 200 mM NaCl, 5 mM CaCl 2 , 0.02% Brij-35, pH 7.5). Finally, gels
were stained with Coomassie Blue and then destained. Completed gels were imaged
using an UVP BioImagining System.

iTRAQ MALDI-TOF/TOF proteome analysis.

The comparative isobaric tags and

relative and absolute quantitation (iTRAQ) analyses of PAO579:PAO579+muiA and
PAO1-VE2:PAO1-VE2+muiA were performed as previously described (5). Briefly, P.
aeruginosa strains PAO579 pHERD26T, PAO579 pHERD26T-muiA, PAO1-VE2
pHERD26T

and

PAO1-VE2

pHERD26T-muiA

were

streaked

on

PIA plates

supplemented with tetracycline and 0.1% L-arabinose and incubated overnight at 37⁰C.
Cells were harvested and whole cell lysates were isolated using the ProteaPrep Cell
Lysis Kit (Protea Biosciences) and total protein content was quantified using the D c
Assay (Bio-Rad). Samples were labeled with isobaric tags for relative and absolute
quantification, and were spotted using an ABI Tempo liquid chromatography-matrix
assisted laser desorption ionization (LC-MALDI) instrument with a Merck Chromolith
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CapRod monolith column. Samples were then further analyzed using an ABI 4800
MALDI-time of flight (TOF/TOF) using ABI ProteinPilot and Paragon software programs.
These data are reported as an average ratio either greater or less than 1, indicating upor down-regulation, respectively. The number of peptides identified with at least 95%
confidence level is also represented, as well as a P-value indicating the certainty that
the average ratio differs from 1. The smaller the P-value, the more likely any differential
expression is significant.
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Results and Discussion
MuiA suppresses the accumulation of low molecular weight products of MucD.
Previously, we found that expression of MuiA failed to suppress mucoidy in the
mucD mutant, indicating a possible relationship between MuiA and the periplasmic
chaperone/protease MucD. To explore this relationship further, we PCR amplified muiA
and fused it into the P BAD -arabinose-inducible shuttle vector pHERD20T (pHERD20TmuiA) (17).

The completed pHERD20T-muiA construct was then conjugated into

PAO579 and the recipient bacteria cultured on PIA plates supplemented with 300 µg/mL
carbenicillin and 0.1% L-arabinose, and incubated for 24 hrs at 37⁰C. Similarly, we
conjugated pHERD20T into PAO1, PAO579 and PAO579ΔalgU, to use as a vector
control. Western blot analysis probing for MucD showed a distinct banding pattern

Figure 1. Western blot analysis of MucD. Shown is a representative panels from three independent
experiments in which 50 μg of whole cell lysate was loaded on a 12.5% Tris-Glycine polyacrylamide gel, electrotransferred, and probed with anti-MucD monoclonal antibody.

consistent amongst all test strains (Figure 1). In PAO1 pHERD20T, we observed full
length MucD at ~50 kDa, and subsequent bands at ~37 kDA, ~30 kDa and ~20 kDa
(Figure 1). These bands observed between ~50 to ~37 kDa are identified as high
molecular weight (High MW), while banding between molecular weights ~30 and ~20
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kDa are identified as low molecular weight (Low MW). Interestingly, we observed an
accumulation of Low MW products in PAO579. Previously, it has been shown that the
MucD homologue in E. coli, DegP, is auto-catalytic (12). Additionally, expression of
mucD is operonic (algUmucABCD), and the regulation occurs at a series of promoters,
two of which are AlgU-dependent (20). We previously showed a significant increase in
transcriptional activity at the AlgU-dependent promoters in PAO579 (22). Therefore, the
accumulation of Low MW products could be due to a combination of increased
transcription of the algUmucABCD operon along with MucD’s ability for auto-proteolytic
activity. Supporting this hypothesis, we observed a decrease in the Low MW products
in the PAO579ΔalgU (Figure 1). MucD has been reported to have an independent
promoter in the region corresponding to mucC, although the sigma factor that drives this
promoter remains unknown (24). In the PAO579ΔalgU strain, the amount of MucD is
reduced when AlgU is not present, suggesting that AlgU is responsible for the
production of MucD.

We also observed that expression of MuiA decreased the

accumulation of Low MW products, again possibly a result of decreased transcriptional
activity at the AlgU-dependent promoter sites of algUmucABCD operon.
MuiA suppresses proteolytic activity at ~50 kDa.
Since MuiA expression suppresses the function of MucD, we wanted to
determine if this activity corresponded to a decrease in periplasmic proteolytic activity.
Previously, we discovered that the regulation of mucoidy in PAO579 requires the
systematic degradation of MucA, initiated by the periplasmic protease AlgW, posibbly
activated by a truncated type IV pilin (22).

Since the expression of MuiA only

suppresses alginate overproduction in P. aeruginosa strains that utilize the degradation
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of the wild-type MucA by AlgW, we would expect to see a decrease in proteolytic activity
for AlgW. Therefore, expression of MuiA should result in a decrease in proteolytic
activity in the periplasm of PAO579. In order to test this hypothesis, we extracted the
total protein from the periplasms of PAO1 pHERD20T, PAO579 pHERD20T,
PAO579ΔalgW

and

PAO579 pHERD20T-muiA.
Equal amounts of protein
were

electrophoretically

separated on 12.5% polyacrylamide gels containing
the

common

proteolytic

substrates zymogen and
casein.

Interestingly, we

Figure 2. Zymogram analysis of protease activty. Analysis of
protease activity of PAO1 pHERD20T, PAO579 pHERD20T (vector
control), PAO579ΔalgW pHERD20T and PAO579 pHERD20T-muiA in
which 25 μg of total protein extracted from the periplasm was loaded on a
12.5% polyacrylamide gel containing zymogen and casein, renatured, and
stained with R250 SuperBlue Coomassie Stain.

did not detect any proteolytic activity at ~41 kDa, the predicted molecular weight of
AlgW, in any of our test strains (data not shown). This may be due, in part, to low
amounts of AlgW found within the cell.

However, we did detect an increase in

proteolytic activity for a ~50 kDa protein (Figure 2) in PAO579 as compared to PAO1.
Additionally, we observed a decreased proteolytic activity of the ~50 kDa protein in
PAO579ΔalgW (Figure 2).

As illustrated in Figure 1, we observed an increase in

expression and activity of the 50 kDa periplasmic protein MucD in PAO579 as
compared to PAO1. The increase in MucD activity may correlate with the increased
proteolytic activity observed at ~50 kDa (Figure 2), however further analysis will be
required to identify the specific protease responsible for this activity. Interestingly, we
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also observed a complete loss of proteolytic activity at ~50 kDa when muiA is expressed
in trans (Figure 2). Collectively, these data suggest the expression of muiA in trans
causes a decrease in proteolytic activity of the protein located at 50 kDa.
Comparative iTRAQ analyses of PAO1-VE2 and PAO579.
To further explore the effect of MuiA on protein profiles of mucoid P. aeruginosa
strains with a wild-type MucA, we used the iTRAQ technology to performed comparative
proteomic analysis of PAO1-VE2 and PAO579 following expression of muiA in trans.
Both PAO1-VE2 and PAO579 are mucoid due to the increased degradation of the wild
type MucA by activated AlgW. Both can be suppressed by muiA in trans. Simply
pHERD26T (vector control) and pHERD26T-muiA plasmids were conjugated into
PAO1-VE2 and PAO579 and cultured on PIA plates supplemented with 200 µg/mL
tetracycline, and expression of muiA was induced by the addition of 0.1% arabinose.
Cultures were incubated at 37⁰C for 24 hrs, cells were collected, and total protein was
extracted. From the proteomic analysis of PAO1-VE2 pHERD26T compared to PAO1VE2 pHERD26T-muiA, we identified 211 distinct peptides, at a 95% confidence value,
that correspond to 35 proteins (Table 2). As expected, the most detected protein was
MuiA (PA1494), due to its overexpression from the multi-copy plasmid, pHERD26TmuiA. Interestingly, we observed an overall down-regulation in most proteins, with the
exception of increases in the outer membrane porin precursor OprO, the conserved
hypothetical protein at gene locus PA4739, and the alginate regulatory protein, AlgP
(Table 2).
Comparative analysis of PAO579 pHERD26T and PAO579 pHERD26T-muiA
identified 95 unique peptides, at a 95% confidence value, that correspond to 12 proteins
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(Table 3). Similar to the analysis of PAO1-VE2 pHERD26T vs. PAO1-VE2 pHERD26TmuiA, the most detected protein was MuiA (average ratio of 6.09).
observed a down-regulation in the remaining proteins.

Overall, we

However, only 3 of the

remaining 10 proteins detected in the comparative analysis of PAO579 pHERD26T vs.
PAO579 pHERD26T-muiA, were also detected in the analysis of PAO1-VE2
pHERD26T vs. PAO1-VE2 pHERD26T-muiA: PA4277 (Elongation Factor-Tu), PA0423
(PasP), PA1800 (tig, Trigger Factor).
Translational Elongation Factor-Tu binds to amino-acylated tRNA, following GTPmediated activation, and assists in transporting it to the A site of the ribosome. After the
dephosphorylation of GTP to GDP, EF-Tu is removed from the tRNA and repeats the
cycle.

EF-Tu is encoded in duplicate on the gene tufA and tufB, and is the most

abundant protein found within the bacterial cell (11, 13). Typically, the amount of EF-Tu
found within the bacterial cell is equimolar with that of tRNA (8, 13). We observed a
1.88- and 1.27-fold down-regulation of EF-Tu in PAO1-VE2 and PAO579 when muiA
was expressed in trans (Table 2 and Table 3). This may be due to the decreased
translation of all the biosynthetic operons including the alginate biosynthetic operon,
although this remains to be determined.
Additionally, we observed a down-regulation in PA1800 in both PAO1-VE2 and
PAO579 when muiA was expressed in trans. The gene loci tig (PA1800), also known
as Trigger Factor, encodes for a 48.6 kDa cytoplasmic chaperone involved in
translocation and prevention of improper molecular interactions with nascent
polypeptides (4, 21). In 2008, Qiu et al. reported that tig, as well as the genes encoding
the cytoplasmic chaperone/ serine protease complex ClpXP, were required for mucoidy
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in the truncated mucA strain PAO581 (18). ClpXP was also reported by Qiu et al to be
responsible for the degradation of the cytoplasmic portion of a truncated MucA (MucA25), and was also required for mucoidy in P aeruginosa strains possessing a wild-type
MucA (18). Thus, the down-regulation of Trigger Factor could be in response to the
overall decrease in the total activity of the proteolytic cascade responsible for the
stabilization of cytoplasmic MucA resulting the loss of mucoidy.
Induction of mucoidy in PAO1-VE2 and PAO579 requires AlgW to initiate the
regulated intramembrane proteolysis of MucA. However, overproduction of alginate in
mucD mutant (PAO1-VE19) requires the site-2 protease MucP, but not AlgW

(6).

Therefore, through the genetic analysis of mucoidy, we found that there are two types of
signals that can activate protease-mediated alginate overproduction: those that activate
AlgW such as mucE, and those that activate MucP through the loss of MucD. Our data
in chapter 4 shows that the expression of MuiA is unable to suppress mucoidy in the
truncated MucA strain PAO581, as well as the mucD mutant PAO1-VE19. As reported
in chapter 4, suppression of mucoidy by MuiA requires an intact N-terminal signal
sequence for proper translocation to the periplasm. These data suggest that MuiA is
only capable of suppressing mucoidy in the AlgW-dependent pathway.
Lastly, we observed a down-regulation in PA0423, or PasP, PAO1-VE2 and
PAO579 when muiA was expressed in trans. PasP is 20.8 kDa protein that possesses
a type I export signal and is secreted to the extracellular matrix (3, 10). Marquart et al.
identified PasP to be an extracellular protease that causes erosion of the corneal
epithelial tissue (14).

Zymogram proteolytic analysis of purified recombinant PasP

showed distinct protease activity at 50 kDa (14). This may explain the decrease in
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proteolytic activity observed at 50 kDa when MuiA is expressed in trans (Figure 2).
Stated more simply, expression of MuiA down-regulates PasP possibly resulting in a
decrease in proteolytic activity at 50 kDa. However, identification of PasP as the 50
kDa protease seen in our experiments remains to be done.
Summary
In this chapter, we explored the possible mechanism by which MuiA suppresses
mucoidy in P. aeruginosa strains with a wild-type MucA. We observed that expression
of MuiA caused a decrease in the accumulation of low molecular weight protein
products in the chaperone/protease MucD. We also observed that expression of MuiA
cause a decrease in proteolytic activity at ~50 kDa.

Finally, comparative iTRAQ

analyses of PAO1-VE2 and PAO579 identified three shared downstream effectors of
MuiA.
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Table 2. iTRAQ proteomic analysis of muiA expression in PAO1-VE2.

Localizationb

Average
Ratioc

Peptides
(95%)

P-Value

P

5.50

43

2.19E-10

C

0.53

28

2.34E-05

O

1.57

13

0.024

P

0.66

12

0.049

PA5556

Name and Functional
Descriptiona
Conserved hypothetical protein,
MuiA
Elongation Factor-Tu
Pyrophosphate-specific outer
membrane porin OprO precursor
Probable binding protein
component of ABC transporter
ATP synthase alpha chain

C

0.70

11

0.037

PA4739

Conserved hypothetical protein

P

1.84

14

0.032

PA0423

PasP

E

0.72

11

0.004

PA3529

Probable peroxidase

C

0.77

10

0.039

PA2300

Chitinase

E

0.74

10

0.019

PA4236

Catalase

P

0.68

9

0.001

PA4266

Elongation factor G

P

0.64

6

0.013

PA4922

Azurin precursor

C

0.57

8

0.016

PA3162

30S ribosomal protein S1
Succinyl-CoA synthetase alpha
chain
Conserved hypothetical protein

C

0.44

5

0.013

C

0.56

6

0.010

C

0.42

6

0.004

Probable iron-sulfur protein
Thiol:disulfide interchange protein
DsbA
Probable outer membrane protein
precursor, LptF
Hypothetical protein

C

0.51

4

0.003

P

0.67

4

0.025

O

0.35

4

0.030

P or O

0.59

3

0.005

Gene Locus
PA1494
PA4277
PA3280
PA1342

PA1589
PA3309
PA4431
PA5489
PA3692
PA4495

109

PA4453

Conserved hypothetical protein

P or O

0.64

3

0.047

PA4935

30S ribosomal protein S6

C

0.41

3

0.025

PA0548

Transketolase DsbB

C

0.55

3

0.027

PA5046

Malic enzyme

C

0.50

4

0.026

PA2743

Translation initiation factor IF-3

C

0.74

2

0.019

PA5173

C

0.47

2

0.030

C

0.49

2

0.018

PA1579

Carbamate kinase
4-hydroyphenylpyruvate
dioxygenase
Hypothetical protein

P or O

0.63

2

0.032

PA1800

tig, Trigger factor

C

0.39

2

0.017

PA2001

Acetyl-CoA

C

0.64

1

0.037

PA5253

Alginate regulatory protein, AlgP

C

1.78

5

0.018

PA0865

PA5161

dTDP-D-glucose 4,6-dehydratase
C
0.58
1
0.026
Probable deoxycytidine
PA3480
C
0.52
1
0.019
triphosphate deaminase
a, PseudoCAP Function Class (www.pseudomonas.com); b, C=cytoplasm; E=extracellular, O=outer membrane,
P=periplasm, U=unknown; c, >1=up-regulated, <1=down-regulated
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Table 3. iTRAQ proteomic analysis of muiA expression in PAO579.

Localizationb

Average
Ratioc

Peptides
(95%)

P-Value

P

6.09

26

1.65E-14

PA4277

Name and Functional
Descriptiona
Conserved hypothetical protein,
MuiA
Elongation Factor-Tu

C

1.27

24

2.77E-06

PA4385

GroEL protein

C

2.24

13

1.48E-07

PA1092

E

1.47

10

0.0076

C

2.04

5

0.040

PA0423

Flagellin type B
Alkyll hydroperoxide reductase
subunit C
PasP

E

0.50

4

0.029

PA3250

Hypothetical protein

C

1.39

4

0.011

PA4386

GroES protein

C or P

0.49

3

0.025

PA1800

tig, Trigger factor

C

0.83

3

0.0039

PA5554

ATP synthase beta chain

C

0.80

2

0.031

Gene Locus
PA1494

PA0139

PA4847

Biotin carboxyl carrier protein
C
0.70
2
0.033
DNA-directed RNA polymerase
PA3480
C
0.72
1
0.031
alpha chain
a, PseudoCAP Function Class (www.pseudomonas.com); b, C=cytoplasm; E=extracellular, O=outer membrane,
P=periplasm, U=unknown; c, >1=up-regulated, <1=down-regulate

111

CHAPTER 5 REFERENCES
1.

2.

3.

4.

5.

6.

7.

8.

9.

10.

11.
12.

13.
14.

Boucher, J. C., J. Martinez-Salazar, M. J. Schurr, M. H. Mudd, H. Yu, and V.
Deretic. 1996. Two distinct loci affecting conversion to mucoidy in Pseudomonas
aeruginosa in cystic fibrosis encode homologs of the serine protease HtrA.
Journal of Bacteriology 178:511-523.
Cezairliyan, B. O., and R. T. Sauer. 2009. Control of Pseudomonas aeruginosa
AlgW protease cleavage of MucA by peptide signals and MucB. Mol Microbiol
72:368-379.
Choi, D. S., D. K. Kim, S. J. Choi, J. Lee, J. P. Choi, S. Rho, S. H. Park, Y. K.
Kim, D. Hwang, and Y. S. Gho. 2011. Proteomic analysis of outer membrane
vesicles derived from Pseudomonas aeruginosa. Proteomics 11:3424-3429.
Crooke, E., and W. Wickner. 1987. Trigger factor: a soluble protein that folds
pro-OmpA into a membrane-assembly-competent form. Proceedings of the
National Academy of Sciences of the United States of America 84:5216-5220.
Damron, F. H., J. P. Owings, Y. Okkotsu, J. J. Varga, J. R. Schurr, J. B.
Goldberg, M. J. Schurr, and H. D. Yu. 2012. Analysis of the Pseudomonas
aeruginosa regulon controlled by the sensor kinase KinB and sigma factor RpoN.
Journal of Bacteriology 194:1317-1330.
Damron, F. H., and H. D. Yu. 2011. Pseudomonas aeruginosa MucD regulates
alginate pathway through activation of MucA degradation via MucP proteolytic
activity. Journal of Bacteriology 193:286-291.
Figurski, D. H., and D. R. Helinski. 1979. Replication of an origin-containing
derivative of plasmid RK2 dependent on a plasmid function provided in trans.
Proceedings of the National Academy of Sciences of the United States of
America 76:1648-1652.
Furano, A. V. 1975. Content of elongation factor Tu in Escherichia coli.
Proceedings of the National Academy of Sciences of the United States of
America 72:4780-4784.
Govan, J. R., and V. Deretic. 1996. Microbial pathogenesis in cystic fibrosis:
mucoid Pseudomonas aeruginosa and Burkholderia cepacia. Microbiol Rev
60:539-574.
Imperi, F., F. Ciccosanti, A. B. Perdomo, F. Tiburzi, C. Mancone, T. Alonzi,
P. Ascenzi, M. Piacentini, P. Visca, and G. M. Fimia. 2009. Analysis of the
periplasmic proteome of Pseudomonas aeruginosa, a metabolically versatile
opportunistic pathogen. Proteomics 9:1901-1915.
Jaskunas, S. R., L. Lindahl, and M. Nomura. 1975. Identification of two copies
of the gene for the elongation factor EF-Tu in E. coli. Nature 257:458-462.
Jones, C. H., P. Dexter, A. K. Evans, C. Liu, S. J. Hultgren, and D. E. Hruby.
2002. Escherichia coli DegP protease cleaves between paired hydrophobic
residues in a natural substrate: the PapA pilin. Journal of Bacteriology 184:57625771.
Kavaliauskas, D., P. Nissen, and C. R. Knudsen. 2012. The busiest of all
ribosomal assistants: elongation factor Tu. Biochemistry 51:2642-2651.
Marquart, M. E., A. R. Caballero, M. Chomnawang, B. A. Thibodeaux, S. S.
Twining, and R. J. O'Callaghan. 2005. Identification of a novel secreted
112

15.

16.

17.

18.

19.

20.

21.

22.

23.

24.

protease from Pseudomonas aeruginosa that causes corneal erosions.
Investigative ophthalmology & visual science 46:3761-3768.
Martin, D. W., B. W. Holloway, and V. Deretic. 1993. Characterization of a
locus determining the mucoid status of Pseudomonas aeruginosa: AlgU shows
sequence similarities with a Bacillus sigma factor. Journal of bacteriology
175:1153-1164.
Martin, D. W., M. J. Schurr, M. H. Mudd, J. R. Govan, B. W. Holloway, and V.
Deretic. 1993. Mechanism of conversion to mucoidy in Pseudomonas
aeruginosa infecting cystic fibrosis patients. Proceedings of the National
Academy of Sciences of the United States of America 90:8377-8381.
Qiu, D., F. H. Damron, T. Mima, H. P. Schweizer, and H. D. Yu. 2008. PBADbased shuttle vectors for functional analysis of toxic and highly-regulated genes
in Pseudomonas and Burkholderia spp. and other bacteria. Applied and
Environmental Microbiology 74:7422-7426.
Qiu, D., V. M. Eisinger, N. E. Head, G. B. Pier, and H. D. Yu. 2008. ClpXP
proteases positively regulate alginate overexpression and mucoid conversion in
Pseudomonas aeruginosa. Microbiology 154:2119-2130.
Qiu, D., V. M. Eisinger, D. W. Rowen, and H. D. Yu. 2007. Regulated
proteolysis controls mucoid conversion in Pseudomonas aeruginosa.
Proceedings of the National Academy of Sciences of the United States of
America 104:8107-8112.
Schurr, M. J., H. Yu, J. M. Martinez-Salazar, J. C. Boucher, and V. Deretic.
1996. Control of AlgU, a member of the sigma E-like family of stress sigma
factors, by the negative regulators MucA and MucB and Pseudomonas
aeruginosa conversion to mucoidy in cystic fibrosis. Journal of Bacteriology
178:4997-5004.
Valent, Q. A., D. A. Kendall, S. High, R. Kusters, B. Oudega, and J. Luirink.
1995. Early events in preprotein recognition in E. coli: interaction of SRP and
trigger factor with nascent polypeptides. The EMBO journal 14:5494-5505.
Withers, T. R., Damron, F.H., Yin, Yeshi, Yu, Hongwei D. 2013. Truncation of
type-IV pilin induces mucoidy in Pseudomonas aeruginosa strain PAO579.
MicrobiologyOpen 2:459-470.
Wood, L. F., A. J. Leech, and D. E. Ohman. 2006. Cell wall-inhibitory antibiotics
activate the alginate biosynthesis operon in Pseudomonas aeruginosa: Roles of
sigma (AlgT) and the AlgW and Prc proteases. Mol Microbiol 62:412-426.
Wood, L. F., and D. E. Ohman. 2006. Independent regulation of MucD, an HtrAlike protease in Pseudomonas aeruginosa, and the role of its proteolytic motif in
alginate gene regulation. Journal of Bacteriology 188:3134-3137.

113

CHAPTER 6: General Discussion and Conclusions
Pseudomonas aeruginosa is an opportunistic pathogen that is primarily
associated with severe respiratory infections in individuals with the autosomal recessive
disorder cystic fibrosis. The ability of P. aeruginosa to readily form a biofilm through the
overproduction of alginate allows for greater adhesion to the lung epithelial cells and
impairs mucociliary clearance (4). Moreover, the overproduction of alginate assists in
the avoiding the host’s immunological response, and confers increased resistance to
the antimicrobial and chemotherapeutic agents (7, 11).

The regulation of alginate

production is primarily controlled by the alternative sigma factor AlgU and its cognate
transmembrane anti-sigma factor MucA.
In non-mucoid environmental strains, AlgU is sequestered to the inner membrane
by the wild-type MucA. However, upon contact with the environment found in the cystic
fibrosis lung, P. aeruginosa quickly transitions from the non-mucoid phenotype to the
alginate overproducing, or mucoid phenotype.

This transition results from two

regulatory mechanisms: First, response to internal or external stressors causes the
release of AlgU through the regulated proteolytic degradation of MucA; Second is the
selection for those strains that possess a “loss of function” mutation in MucA. It is
generally accepted that those early colonizing strains utilize the proteolytic degradation
of MucA for induction of alginate overproduction prior to the selection for mutations in
MucA.

Moreover, this transition from the non-mucoid to the mucoid phenotype is

emblematic of a decline in the overall health in individuals afflicted with cystic fibrosis
(9). Therefore, it is beneficial to understand the regulatory mechanisms responsible for
the conversion to mucoidy in those P. aeruginosa strains with a wild-type MucA, in order
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to prevent a chronic respiratory infection. The overall goal of this dissertation was to
identify and characterize novel regulators of alginate overproduction in those P.
aeruginosa strains carrying a wild-type MucA. In this chapter, I will review and discuss
the research detailed in this dissertation and suggest future studies.
In Chapter 2, we used next generation sequencing to identify those mutations
that are unique to the P. aeruginosa strain PAO579.

Based on our comparative

genomic analysis, we identified 31 mutations that were present in PAO579 but were not
present in PAO1 (Chapter 2, Table 1). Of these 31 mutations, 16 were classified as
non-synonymous, while the remaining 15 were classified as synonymous mutations. As
expected, we identified mutations in the leuA and rpsL genes, corresponding to the
leucine-axotrophic and streptomycin-resistant phenotypes observed in PAO579.
Interestingly, we identified a single nucleotide polymorphism resulting in a nonsynonymous mutation in the DegS-like serine protease AlgW. AlgW has been shown to
confer mucoidy in P. aeruginosa by proteolytically degrading the transmembrane antiAlgU factor, MucA (3, 15). Also of importance, we identified three sequential mutations
in pilA, a gene encoding the precursor for type-IV pilin. Therefore, next-generation
sequencing is an excellent tool for comparative genomic analyses and the identification
of classical mutations
In Chapter 3, I determined which mutations, identified through the sequencing
analysis detailed in Chapter 2, were ultimately responsible for conferring mucoidy in
PAO579.

Using standard molecular techniques and complementation analyses, I

determined that the sequential mutations present in the pilA gene were responsible for
the induction of mucoidy in PAO579. Further analyses determined that these sequential
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mutations result in a truncation in the PilA protein, revealing a C-terminal amino acid
motif of phenylalanine-threonine-phenylalanine (FTF), which causes a release of the
alternative sigma factor AlgU following the proteolytic degradation of MucA by AlgW.
Previously, Boucher et al. reported that the sigma factor RpoN was required for mucoidy
in PAO579, while the alternative sigma factor AlgU was not required for mucoidy (2).
Based on their analysis, they suggested that the use of RpoN in place of AlgU for the
induction of mucoidy was due to sigma factor antagonism (2).

My results suggest

otherwise. I did observe that RpoN is required for mucoidy in PAO579, however my
data suggests that this is due to RpoN’s role in regulating transcription of AlgW and the
truncated PilA.

Therefore, my results indicated that RpoN acts upstream of algD.

Further supporting this model, I observed that the deletion of AlgU resulted in loss of
mucoidy, confirming AlgU’s role in regulating mucoidy in PAO579. I also observed that
the truncated PilA protein did not localize to the cell surface, due to decreased stability.
Taken together, the results from chapters 2 and 3 clearly outline a pathway in
which truncated pilin can confer mucoidy in P. aeruginosa strains possessing a wildtype MucA.

However, these results pose many interesting questions.

First, will

exposure to subclinical doses of carbenicillin consistently select for mucoid colonies
containing these same mutations? This could be determined by repeating the previous
experiments conducted by Govan and Fyfe (8), with the addition of PCR and sequence
analysis targeting the particular genetic loci identified in this study. Second, what is the
clinical relevance of the sequential mutations causing a truncation of type-IV pilin?
Simply stated, are these mutations found in clinical isolates? Based on my preliminary
analysis, I was unable to detect the three sequential mutations in pilA found in PAO579
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in clinical strains possessing a wild-type MucA. However, I was only able to examine a
small sample size of early colonizing clinical isolates possessing a wild-type MucA.
Expanding this analysis to included hundreds of clinical isolates could help determine
the clinical relevance of this mutation.

Finally, does the truncation of PilA have a

synergistic effect regarding evasion from the host’s immune system? I determined that
the truncated PilA found in PAO579 does not localize to the cell surface due to an
overall lack of stability.

PilA is a known immunogenic target for macrophages and

neutrophils (12, 16).

Simultaneously, the truncation of PilA activates alginate

overproduction, providing additional protection from the host’s immunological response
(11). Additional experiments analyzing immunological markers should be performed to
determine whether this synergistic relationship is present. Specifically, western blot
analyses targeting interleukin-8 in CF- and non-CF cell lines cultured in the presence of
PAO579 could best characterize this relationship. Together, these future studies will
identify the prevalence and relevance that mutations resulting in the truncation of type
IV pili have with respect to the formation of a mucoid biofilm, and the development of a
chronic respiratory infection.
In Chapter 4, I shifted the focus of my study to identifying possible genetic
mechanisms to prevent the formation of a mucoid biofilm. To do so, I expanded upon
the initial observations of a previous graduate student, Dr. Nathan Head. In this study,
he used whole genome complementation analysis using a PAO1-derived cosmid library,
coupled with in vitro transposon-mediated mutagenesis, to identify possible inhibitors of
alginate overproduction.

These experiments were performed using PAO579 as the

model strain; however these results were preliminary due to a lack of data determining
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the precise mechanism by which PAO579 conferred mucoidy.

As a result of my

continuance of this study, I identified the expression of gene locus PA1494 can inhibit
mucoidy in P. aeruginosa strain PAO579.

Moreover, expression of PA1494, also

referred to as mucoid inhibitor A (muiA), suppressed mucoidy in strains possessing a
wild-type MucA. This was not observed in mucoid P. aeruginosa strains with MucA
mutations.

MuiA’s ability to suppress alginate overproduction required correct

localization to the periplasm. This finding supports previous reports identifying MuiA as
a periplasmic protein (10).

Interestingly, characterization of MuiA based on sequence

analysis identified no homologs in other Pseudomonads or E. coli. While this study
identifies MuiA as a potential target for the suppression of mucoid biofilm formation,
many questions remain regarding the role of MuiA within the cell.

Primarily, what

function does MuiA play in the physiology of P. aeruginosa? To answer this question,
X-ray crystallography analysis of the protein could be performed to determine the threedimensional structure of MuiA, as well as identify any potential active sites or binding
domains. Additionally, identifying those proteins which interact with MuiA within the
periplasm could be particularly useful information in determining MuiA’s function. Since
the expression of MuiA was unable to suppress mucoidy in the absence of the
periplasmic serine protease MucD, then, generally speaking, the mechanisms that
activate protease-mediated alginate overproduction can be classified into two types.
The first mechanism requires the activation of AlgW to initiate the degradation of MucA
(3, 5, 15, 17), while the second occurs following the inactivation of MucD, and
subsequent activation of the site-2 protease, MucP (6). Despite this analysis, additional
experiments to identify and characterize proteins that specifically interact with MuiA
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should be performed. Techniques such as the co-immunoprecipitation of MuiA, as well
as bacterial of yeast two-hybridization, should be performed, with priority given to
proteins found within the periplasm. Comparison of the results garnered from these
methods could provide potential candidates for further analysis.
Experiments further examining the relationship between MuiA and MucD are
presented in chapter 5. MucD is a periplasmic serine protease that has considerable
homology with the protease DegP found in E. coli (1). Moreover, MucD plays a role in
both the suppression and induction of mucoidy in P. aeruginosa (1, 6, 19, 20). Western
blot analysis probing for MucD revealed an accumulation of lower molecular weight
bands in the mucoid strain PAO579, when compared to the non-mucoid progenitor
strain PAO1. However I did not observe the level of accumulation of lower molecular
weight bands when the alternative sigma factor AlgU was deleted in PAO579. Also,
expression of muiA in trans reduced the amount of lower molecular weight bands in
PAO579 to levels comparable to PAO1. Collectively, these data suggest that there is
an increase in expression of mucD in PAO579 as compared to PAO1. Moreover, we
observed a decrease in the accumulation of lower molecular weight products in
PAO579ΔalgU, suggesting that the increased expression of mucD in PAO579 is likely
due to auto-regulation of the algUmucABCD operon by AlgU. However, these data do
not identify a clear association between MuiA and MucD outside of MuiA’s ability to
suppress the release of AlgU. Based on these results, I wanted to determine if the
expression of muiA affected proteolytic activity in PAO579.

I observed increased

proteolytic activity at ~50 kDa. Moreover, we also observed a decrease in proteolytic
activity at ~50 kDa when MuiA is expressed in trans. These data possibly corresponds
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to the proposed increased expression of MucD in PAO579, suggested in the previous
western blot analysis, however the specific protease needs to be determined using
either tandem mass spectroscopy or de novo peptide sequencing.

In future studies,

the possible relationship between of MuiA and MucD could be succinctly determined
using in vitro protein-protein interaction assays, or through bacterial two-hybridization.
The comparative iTRAQ proteomic analyses to identify changes in the protein
profiles of mucoid strains PAO579 and VE2, due to the expression of muiA in trans is
presented in chapter 5. Based on these analyses, we identified three common proteins
effectors down-regulated in both VE2 and PAO579 when muiA is expressed in trans:
Elongation Factor-Tu (EF-Tu), Trigger Factor and the extracellular protease PasP. The
down-regulation in EF-Tu could be in response to the decrease in expression of the
alginate biosynthetic operon; however this remains to be determined. Previously, Qiu et
al. identified Trigger Factor as being required for the proteolytic degradation of the
cytoplasmic portion of MucA (14). Therefore, the down-regulation of Trigger Factor may
be in response to the decrease in regulated intramembrane proteolysis of MucA. An
interesting protein down-regulated by expression of muiA is PasP. This extracellular
protease is associated with corneal pathogenicity, and causes proteolytic degradation at
~50 kDa (13). These findings correlate with the decrease in proteolytic activity at ~50
kDa observed in the prior zymogram protease analysis of PAO579. Tandem mass
spectroscopy is needed to determine whether the protein responsible for the increased
protease activity at ~50 kDa is PasP.
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Summary and Conclusions
The goal of this thesis was to identify novel regulators of alginate overproduction, also
known as mucoidy, in P. aeruginosa strains possessing a wild-type MucA. The work in
Chapters 2 and 3 identified the mutations resulting in the truncation of type-IV pili and
demonstrated that this mutated protein can induce mucoidy via the regulated
intramembrane proteolysis of wild-type MucA in the model strain PAO579. Chapters 4
and 5, describe the identification and characterization of a novel inhibitor of alginate
overproduction in P. aeruginosa strains possessing a wild-type MucA. An illustration
summarizing the findings presented in this dissertation can be found on page 114
(Figure 1).

However, many questions remain regarding the prevalence and clinical

relevance of truncated type-IV pili-mediated alginate overproduction, and the
mechanism by which MuiA suppresses mucoidy in P. aeruginosa.
There has been a considerable amount research focusing on the role of the
alternative sigma factor AlgU and its cognate anti-sigma factor MucA in the regulation of
alginate overproduction in P. aeruginosa. Previous studies have shown the importance
of mucA mutations in establishing a chronic infection within the cystic fibrosis lung
through the formation of mucoid biofilm. However, there are few studies that identify the
genetic regulatory components involved in induction of mucoidy prior to selection for
MucA mutants. In this study, I identified and characterized two novel regulators that
control alginate overproduction in strains possessing a wild-type MucA. Understanding
the mechanism by which these regulators control alginate overproduction will give us a
better understanding of the progression from the non-mucoid to the mucoid phenotype
in early colonizing strains of P. aeruginosa. More importantly, the identification of novel
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inhibitors of alginate overproduction may provide a solution for preventing the
establishment of chronic respiratory infection in individuals afflicted with cystic fibrosis.

122

Figure 1. Illustration summarizing the research contained in this dissertation. In PAO579, three
tandem mutations coding a premature stop codon in pilA results in the truncation of the pilin protein to
108
108 amino acids (PilA108) (18). The sigma factor RpoN drives for transcription of pilA (muc-23) and
algW (not shown). PilA108 possesses a C-terminal motif of phenylalanine-threonine-phenylalanine
(FTF) which activates the periplasmic protease AlgW after translocation to the periplasm (17). Upon
activation, AlgW initiates the proteolytic degradation of MucA, thereby releasing AlgU. The release of
AlgU drives transcription at the alginate biosynthetic operon. Expression of MuiA suppresses alginate
overproduction following localization to the periplasm. IM, inner membrane; OM, outer membrane.
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